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Abstract
The sigma-1 receptor (σ1) is a single 25 kD polypeptide that acts as a chaperone
protein residing primarily in the endoplasmic reticulum . Its interaction with mitochondria
at the mitochondria-associated ER membrane domain is well-documented. Following
agonist activation, σ1 binds to the inositol trisphosphate receptor which modulates
intracellular calcium homeostasis. Also, the activated σ1 modulates plasma membrane
receptors and ion channel functions, and may regulate cellular excitability. Further, σ1
affects trafficking of lipids and proteins essential for neurotransmission, cell growth and
motility. Activation of σ1 provides neuroprotection and cardio-protection in various
models. Examples of neuroprotection include but not limited to the use of σ1 agonists
as therapeutic targets in neuro-psychiatric disorders, cognitive disorders,
neurodegenerative diseases, pain and stroke.
In regards to cardio-protection, Bhuiyan et al have shown that cardiac σ1
receptors have a role in ameliorating cardiac hypertrophy in pressure overload induced
heart failure model. In addition to neuro- and cardio-protection, some studies have
shown different actions of σ1 in endothelium such as enhancement of nitric oxide
production or modulation of calcium homeostasis. The recent finding by Dan-Yang Liu
et al that σ1 activation alleviates blood brain barrier dysfunction in vascular dementia
mice suggests its role in maintaining endothelial junctional integrity, which has not
previously been studied in detail.
xvi

In the current project we investigated the potential involvement of σ1 receptors in
enhancing endothelial barrier function and modulating arteriolar diameter pursuing both
genetic and pharmacological approaches. We assessed the extent to which σ1
activation can protect endothelial cells from barrier disrupting agents such as the
inflammatory cytokine IL-1β or the mitochondrial ionophore Carbonyl cyanide mchlorophenyl hydrazine. σ1 receptor activation is known to maintain mitochondrial
integrity, improve cell survival and stress response via mitochondria and regulate
oxidative stress derived from mitochondria based on their localization at mitochondria
associated ER membrane in neurological models. However, there is lack of studies
about its effects in regard to endothelial mitochondria or bioenergetics particularly
glycolysis. The present project will outline its role in maintaining endothelial barrier
integrity with respect to endothelial junctional proteins and endothelial bio-energetics.
Several reports suggest that σ1 activation improves outcomes following stroke
injury. Previously identified mechanisms include preserving calcium homeostasis and
glial cell function, lowering infarct volume. Our recent study shows that σ1 agonism by
afobazole relaxes rat mesenteric lymphatic vessels. The response was attenuated by
the NO synthase inhibitor L-NAME. Furthermore, afobazole was shown to elicit elevated
NO production in cultured lymphatic endothelial cells. Other studies have also
suggested the potential link between σ1 an eNOS. Bhuiyan et al have demonstrated
that σ1 agonism by DHEA treatment induces stimulation of Akt-eNOS signaling
pathways in rat thoracic aorta. They have also shown that σ1 activation protects against
hypertension-induced kidney injury by stimulation of Akt-eNOS signaling pathway. Thus,
in the current project in addition to studying intracellular mechanisms, we also

xvii

investigated the ex vivo role of σ1 activation in brain arteriolar diameter and also human
arteriolar diameter modulation.
In summary, we elucidated several previously unreported roles of σ1 in
endothelium. We found that σ1 is critical and important in maintaining basal endothelial
barrier integrity. We also highlighted the role of σ1 activation in eNOS activation and NO
production. We reported that the effect of σ1 activation on endothelial barrier is tightly
linked to shifting metabolic pathways towards enhancing glycolysis and glycolytic ATP
production, which is important in maintaining barrier function. Future studies are needed
to examine more pathways involving σ1 signaling in endothelial cells and validate these
pathways in animal models.

xviii

Chapter One:
Introduction
1 a. Endothelium Overview.
Endothelium is the innermost layer that lines blood vessels and it has an
important role in controlling fluid and solute movement between blood and tissues. It
also contributes to homeostasis, blood fluidity, fibrinolysis, inflammation and regulation
of vascular tone (Rubanyi, 1993; Sandoo et al., 2010; van Hinsbergh, 2012). The barrier
function of the endothelium depends on the integrity of endothelial structure which
undergoes changes in response to various stimuli (Yuan & Rigor, 2010). Endothelial
cells are constantly exposed to fluid shear stress and express important junctional
proteins that allow for optimum barrier function. These junctional proteins include tight
junctions such as claudins or occludins, adherens junctions such as VE-Cadherin or
beta catenin. PECAM-1 is another junctional molecule which is not associated with tight
or adherens junctions (Cerutti & Ridley, 2017).
The endothelium is considered an important organ system that is composed of a
cell layer that is involved in many physiologic functions, such as the control of
vasomotor tone, movement of cells and nutrients, the maintenance of tissue microenvironment, and angiogenesis(Aird, 2004). The location of endothelium between
blood and tissues highlights its importance in fluid and nutrient movement across this
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layer (Cines et al., 1998). The endothelium also plays a humoral function by secretion of
many biologically active substances such as prostacyclin, nitric oxide(Vane & Botting,
1992). Endothelium plays a major role in homeostasis and can protect against
thrombosis and maintain blood fluidity(Verhamme & Hoylaerts, 2006).
To keep blood fluidity, endothelial cells counteract coagulation by providing tissue
factor and thrombin inhibitors and receptors for protein C activation including the
receptor PAR-1 which has anti thrombotic and anti inflammatory effects(van Hinsbergh,
2012). The endothelium has an important fibrinolytic activity achieved by production of
type-1 plasminogen activator inhibitor which is one of the highly regulated fibrinolytic
component produced by endothelial cells(Schleef & Loskutoff, 1988).
The endothelium plays a vital role in providing nutrients to underlying tissues and
maintain the oncotic pressure(Sukriti et al., 2014). Endothelium arises from mesoderm
from embryonic precursor cells called hemangioblasts with the help of bone
morphogenic protein(Dyer & Patterson, 2010). From this hemangioblast originates
endothelial progenitor cells that forms endothelial cells that line arteries or veins or
capillaries which will then form different types of capillaries such as the capillaries
forming the blood barrier which are characterized by having a lot of tight junctions which
protects the brain against passage of pathogens whereas liver capillaries have large
fenestrae(Aird, 2012).
Vascular permeability reflects the flux of small molecules between blood to
tissues even in un-stimulated setting with molecules smaller than 40 kDa, whereas
molecules with larger molecular weight requires disruption of the vascular
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barrier(Claesson-Welsh, 2015) . Vascular permeability is established through either
paracellular or transcellular routes (Komarova & Malik, 2010).
Endothelium also plays a pivotal role in leukocyte trafficking(Panes et al., 1999).
There are several molecules that can control leukocyte-endothelial adhesion including
but not limited to selectins, ICAM-1 and VCAM-1/INCAM-110(Bevilacqua, 1993). It has
been previously well documented that endothelial barrier regulation is involved in
leukocyte trafficking(Goswami & Vestweber, 2016; Alon & van Buul, 2017).
Another important role of endothelial cells is their role in angiogenesis. During
vessel formation, endothelial cells known as tip cells migrate to the front and the stalk
endothelial cells elongate the sprout(Vandekeere et al., 2015). This dynamic process
requires activation of multiple signaling pathways that involve endothelial cytoskeletal
remodeling(Lamalice et al., 2007). Examples including the key regulators of
angiogenesis are vascular endothelial growth factor (VEGF), Notch and Planar Cell
Polarity (PCP)(Sewduth & Santoro, 2016).
Vascular endothelium also has a pivotal role in metabolic homeostasis (Pi et al.,
2018). It has been shown to regulate the transport of lipids, lipoproteins, glucose and
insulin and dysregulation of endothelial processes results in metabolic disturbance(Pi et
al., 2018).

1 b. Endothelial Integrity.
Endothelial barrier is an important function of endothelium and is controlled by a
certain number of junctional proteins. Junctional proteins include tight junctions or
adherens junctions(Hartsock & Nelson, 2008). Adherens junctions include E-Cadherin,
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VE-Cadherin, N-Cadherin and the catenin family including β-catenins, α-catenins and p120 catenins(Hartsock & Nelson, 2008). There is another family of junctional proteins
which are the tight junctions such as claudins and occludins that functions as a fence
that prevents the mixing of membrane proteins between the apical and basolateral
membranes and also functions as a gate that controls the paracellular passage of ions
and solutes between cells(Hartsock & Nelson, 2008).
Cytoskeleton also plays an important role in regulation of vascular barrier. In
endothelial cells, the process of actin polymerization is very dynamic(Bogatcheva &
Verin, 2008). The endothelial cytoskeleton is composed of actin filaments (F-actin),
intermediate filaments and microtubules whereas the contractile machinery composes
of actin and myosin and includes a signaling mechanism involving myosin light chain
kinase (MLCK)(Shen et al., 2009). It has been shown that disturbance of either actin or
microtubule microfilaments is associated with paracellular gaps and permeability
increase in microenvironment (Kasa et al., 2015).
Lamellopodia are thin flat membranous cellular protrusions that are formed at the
leading edge or periphery of moving or migrating cells and are rich in actin
filaments(Rikitake & Takai, 2011; Fu et al., 2018) Lamellopodia dynamics is another
important parameter affecting endothelial barrier. It has been shown that in addition to
the relatively high significant contribution of stable junctional adhesions such as VECadherins, local lamellopodia represent a more dynamic endothelial junction that also
contribute to barrier integrity(Breslin et al., 2015a).
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1 c. Endothelium in diseases.
Endothelial dysfunction is the hallmark of many disease conditions including but not
limited to stroke, myocardial infarction, diabetes, renal failure or peripheral arterial
disease (Chia et al., 2005; Hadi & Suwaidi, 2007; Malyszko, 2010; Blum et al., 2012;
Igari et al., 2016). Endothelial dysfunction is tightly related to inflammation(Castellon &
Bogdanova, 2016) which is mostly linked to release of inflammatory mediators such as
IL-1β, TNF-α, INF-γ(Zhang, 2008). These mediators have been shown to disrupt
endothelial barrier and enhance permeability by various mechanisms (Marcos-Ramiro
et al., 2014; Du et al., 2015; Ng et al., 2015). Endothelial dysfunction is characterized by
change of endothelial function towards reduced vasodilation, pro-inflammatory state and
reduced vasodilation(Endemann & Schiffrin, 2004).
There have been multiple evidences of endothelial dysfunction in
stroke(Cosentino et al., 2001). It has been linked to stroke physiopathology, stroke
subtypes, clinical severity and outcome(Roquer et al., 2009). Blum et al have shown
that recent acute ischemic stroke is associated with impaired vascular functions in
humans(Blum et al., 2012). Another study showed the significant vascular remodeling
that occurs following stroke(Liu et al., 2014). Ischemic damage of brain microvessels
following stroke has been also reported(del Zoppo et al., 1998). Brain edema has been
documented as a consequence of ischemic stroke(Dostovic et al., 2016; Thoren et al.,
2017; Wu et al., 2018) and has been linked to endothelial dysfunction(Aman et al.,
2012; Michinaga & Koyama, 2015).
Another evidence of endothelial dysfunction in stroke is that basal levels of nitric
oxide appear to be disturbed (Stagliano et al., 1997; Castillo et al., 2000; Nemoto, 2000;
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Cui et al., 2009; Chen et al., 2017). Castillo et al have shown that pathological levels of
NO in CSF following stroke are associated with greater brain injury and early
neurological deterioration(Castillo et al., 2000). Nitric oxide levels have also been
associated with blood brain barrier disruption(Chi et al., 1997; Mohammadi et al., 2012).
Blood brain barrier disruption and associated brain edema has been shown as a
consequence of stroke(Hoffmann et al., 2018). Abdullahi et al have shown that BBB
disruption in stroke is linked to tight junction disruption and modulation of functional
expression of endogenous BBB transporters(Abdullahi et al., 2018). Multiple factors
contribute to BBB damage in stroke including cytokines, chemokines, oxidative and
nitrosative stress, adhesion molecules, matrix metalloproteinases, and vascular
endothelial growth factor(Yang et al., 2019a). Not only stroke induced BBB disruption
involves endothelial damage, but also involves dysfunctions of other components of the
neurovascular unit including pericytes, astrocytes and neuronal cells(Barreto et al.,
2011)
Inflammation is another contributor to stroke related microvascular damage. The
immune response starts to react locally around infarct area and the inflammatory
mediators can lead to a systemic inflammatory response(Anrather & Iadecola, 2016).
This involves leukocyte infiltration and microglial activation(Jin et al., 2010). The
affection of brain endothelial cells by stroke related inflammation further aggravates the
problem. It has been well established that endothelial cells are major regulators and
participants of inflammatory reactions(Pober & Sessa, 2007). Cytokines that are known
to be released in stroke could negatively regulate barrier function in brain endothelial
cells(Lopez-Ramirez et al., 2012).
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Another clinical relevance of endothelial dysfunction is myocardial
infarction(Bhagat, 1998). Circulating endothelial cells are recognized as a measure to
predict occurrence of myocardial infarction(Damani et al., 2012). Ischemia/ Reperfusion
injury in the heart following myocardial infarction can lead to endothelial dysfunction that
can be represented by activation of the humoral and cellular components of the
hemostatic and innate immune system, and also with excessive production of reactive
oxygen species (ROS), the inhibition of nitric oxide synthase and inflammatory
processes(Hernandez-Resendiz et al., 2018).
Other diseases that involve endothelial dysfunction include but not limited to
hypertension, Raynaud’s disease, diabetes, renal failure, pre-eclampsia, peripheral
arterial disease, dementia, vision loss and erectile dysfunction(Freedman et al., 1999;
Puddu et al., 2000; Bivalacqua et al., 2003; Brevetti et al., 2003; Hadi & Suwaidi, 2007;
Malyszko, 2010; Kiprono et al., 2013; Shen et al., 2017; Wang et al., 2018a). Due to the
involvement of endothelial dysfunction in these diseases and others, there has been a
continuous need to find agents that can improve endothelial health in many disease
conditions. This study targets finding new avenues for endothelial protection through
sigma-1 agonism in endothelial cells.

1 d. Sigma-1 Receptor Overview.
Biology of σ1
When it was first discovered through pharmacological methods, the σ1 receptor
was initially described as an opioid receptor based on behavioral observations by Martin
et al who named it as the sigma/opioid receptor(Gilbert & Martin, 1976). However, in the
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same paper, Martin observed that they the σ agonists benzomorphans don’t cause
analgesia as the other opioid receptor agonist morphine, but does contribute to delusion
an psychosis caused by opioids(Gilbert & Martin, 1976). Su et al used the sigma opioid
receptor ligand SKF-10047 to identify a protein that had a nanomolar affinity for SKF10047 and no affinity for the opioid antagonist naloxone(Su, 1982). This finding
suggested that the protein identified by Su may not be a true opioid receptor(Hayashi &
Su, 2005). Accordingly, this protein was then designated simply as the “sigma receptor”
to differentiate it from opioid receptors(Hayashi & Su, 2005) .
Two subtypes of σ receptors have been described based upon pharmacological
properties, σ1 and σ2. Each has been reported to have distinct cellular and
physiological functions(Hayashi & Su, 2005). The gene that encodes σ1 was first
successfully cloned by Hanner et al in 1996.(Hanner et al., 1996). Since then, σ1 has
gained considerable attention pertaining to its function in cell biology, molecular biology,
cancer, immunology, and behavioral neuroscience(Terada et al., 2019). On the other
hand, σ2 is thought to be involved in cellular processes related to neuropathy(Terada et
al., 2019), as well as cancer biology and has been proposed as a potential drug target
in cancer therapy(Crawford et al., 2002) In 2017, Alon et al reported that the gene
TMEM97 encodes σ2(Alon et al., 2017).
σ1 is now known to be a chaperone protein that is ubiquitously expressed and
typically located in the endoplasmic reticulum(Maurice & Su, 2009). Encoded by the
SIGMAR1 gene, σ1 is a non-G-protein-coupled transmembrane protein(Cobos et al.,
2008). The carboxy-terminal domain of the receptor is flat and hydrophobic associated
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with the cytosolic surface of the ER membrane in cells and includes the ligand binding
site(Schmidt et al., 2016).
The overall structure of the σ1 receptor constitutes of a trimeric organization with
a three-fold non-crystallographic symmetry axis normal to the membrane plane. The
receptor contains a single transmembrane domain for each protomer, in contrast to to
the prevailing models of a two-pass transmembrane architecture. The carboxy-terminal
membrane-adjacent domains forms the trimeric structure of the receptor, packing
together with an interface of ~9300 Å2 between each adjacent pair of
protomers(Schmidt et al., 2016).
Regarding its differential expression in tissues, it has been shown that σ1
receptor is expressed plentifully in the liver and relatively in the intestine, kidney, white
pulp of the spleen, adrenal gland, brain, placenta and the lung. Also, numerous cancer
cell lines express the σ1 receptor. In brain it was reported that σ1 is expressed
primarily in cranial nerve nuclei, mesencephalon, red nucleus, periaqueductal gray
matter and substantia nigra, as well as in some diencephalic structures including
paraventricular and ventromedial hypothalamic nuclei(Hayashi & Su, 2005). Although
several studies have reported high expression of σ1 in various brain regions, there is
actually very high mRNA levels in vascular tissue and some other tissues based upon
findings in the GTEx portal database (Figure 1). Bhuiyan et al have confirmed the
expression of σ1 in rat left ventricle(Bhuiyan et al., 2010), while Trujillo et al have
successfully showed its expression in rat lymphatic vessels (Trujillo et al., 2017).
Expression of σ1 in the liver was also shown by Pal et al (Pal et al., 2012).
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Langa et al successfully generated a σ1 knock out mice to enable study of the
definitive functions of this receptor in vivo(Langa et al., 2003). Using this model, work by
Sabino et al suggests that σ1 receptors inversely modulate depressive-like behavior in
mice as they showed that σ1 knockout mice had increased depressive like behavior in
the forced swim test by having more immobility behavior and less swimming behavior
(Sabino et al., 2009). The involvement of σ1 in plasticity and synaptic transmission was
evaluated by Snyder et al, who showed that σ1 knockout mice do not have altered
neuronal excitability or post synaptic function, but do have reduced long term
potentiation compared to control mice(Snyder et al., 2016). Moreover, using σ1
knockout mice revealed its importance in neurogenesis in the dentate gyrus, as σ1
knockout mice displayed enhanced proliferation of progenitor cells, reduced survival
and neurite outgrowth of newborn neuron, and down regulation of NMDA receptors(Sha
et al., 2013).
Chemistry and pharmacology of the σ1 agonist PRE-084
PRE-084 is a highly selective σ1 agonist that was first identified and introduced
by Su et al in 1991 who characterized its derivation from phencyclidine(Su et al., 1991).
With its chemical formula C19H27NO3 (Fig. 2), it contains the three basic units for a σ
ligand which are a hydrophobic cluster, an amine group and an intermediate chain (Su
et al., 1991). With conformational analysis, PRE-084 fitted well onto the pharmacophore
models of σ binding with minimal cross reactivity with many other receptors (Su et al.,
1991). The binding between σ1 receptor and PRE-084 was also confirmed by the use of
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reverse phase liquid chromatography in mouse blood, brain and spinal cord which was
the first in vivo analysis of PRE-084 binding(Marra et al., 2016).
Some σ1 agonists have been successfully used in clinical trials. For example, the
σ1 agonist SA-4503 (Cutamesine) has been used in clinical trials for stroke patients
where it was administered starting 48 hours to 72 hours following stroke at the doses of
either 1 mg/day or 3 mg/day for 28 days(Urfer et al., 2014). Cutamesine was proven
safe and well tolerated by patients and the dose of 3mg/day significantly improved NIH
stroke scale in patients versus placebo(Urfer et al., 2014). Another σ1 agonist igmisine
significantly improved depression in another clinical trial(Hayashi & Su, 2004).
The σ agonist afobazole is approved for use in Russia as anti anxiolytic after it
passed several clinical trials(Reutova et al., 2010). It showed higher tolerability and
patient acceptability in comparison to benzodiazepines (that works through GABA
receptors (Griffin et al., 2013), (Reutova et al., 2010; Syunyakov & Neznamov, 2016). It
was tried in patients with generalized anxiety disorders (GAD) and adjustment disorders
(AD)(Reutova et al., 2010). Afobazole caused a significant reduction of Hamilton
Anxiety Rating Scale (HAMA) total score that exceeded diazepam(Syunyakov &
Neznamov, 2016). After treatment completion, no manifestations of afobazole
withdrawal syndrome were found while diazepam withdrawal syndrome was observed in
(68%) patients(Syunyakov & Neznamov, 2016).
Different σ1 receptor ligands entered Phase II clinical trials in the 1990s and in
early 2000s with the goal of producing a new treatment of neuro- psychiatric disorders,
however these drugs did not move into Phase III clinical trials(Smith, 2017). Some σ1
antagonists have been used in clinical trials. For example, panamesine (EMD57445)
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was used in a trial for schizophrenia and could decrease the Brief Psychiatric Rating
Scale score by at least 50% in half of the participants(Frieboes et al., 1997). In addition,
the σ1 antagonist haloperidol is clinically used as a prototypical antipsychotic(Dold et
al., 2015)
After preclinical studies reported the role of σ1 antagonists in pain treatment,
they were assigned to enter Phase II clinical trials. S1RA was first used in a phase 1
clinical trial and was shown not to have effects on visual memory, executive function,
attention or somnolence, while it caused some transient slowing of response for simple
reaction time and choice reaction time at 2 h following the treatment with higher
doses(Abadias et al., 2013). S1RA is currently being tested in phase II clinical trials for
neuropathic pain treatment and as an adjuvant to opioid analgesia(Abadias et al.,
2013). In addition, some σ1 agonists as PRE-084, and σ1 antagonists as BD-1047 and
S1RA have tested successfully for safety and tolerability in Phase I clinical trials and
they are the first σ1 ligands developed in aim of pain treatment(Smith, 2017). More
potential applications and use of σ1 agonists, especially PRE-084 in clinical trials will be
highlighted in this review.
Sigma-1 Receptor as neuroprotective.
Sigma-1 agonists have been shown to be beneficial in many neurological
diseases including stroke, amyotrophic lateral sclerosis, Parkinson’s disease,
Alzhiemer’s disease a long with their neuroprotective action against glutamate
excitotoxicity, calcium dysregulation, ER stress and neuroinflammation(Nguyen et al.,
2017). Sigma-1 receptor agonist SA-4503 has been shown to be beneficial in phase 2
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stroke clinical trial(Urfer et al., 2014). Sigma-1 receptor agonism could also reduce ER
stress in stroke mice(Morihara et al., 2018).
Impacts of PRE-084 on neural tissue:
Sigma-1 activation by PRE-084 has been proven neuroprotective and an
enhancer of neuro-development in various models. Saulite at al reported that σ1
activation with PRE-084 could facilitate differentiation of skin mesenchymal stem cells to
Schwann cells by increasing myelin basic protein expression (Saulite et al., 2018).
Another study suggests that PRE-084 improved nerve growth factor-induced neurite
outgrowth inhibition by dexamethasone in pheochromocytoma cells probably by TrKB
signaling(Kimura et al., 2013). Neurite elongation by PRE-084 was also linked to protein
kinase C (PKC) signaling on motoneurons(Guzman-Lenis et al., 2009). PRE-084 also
enhanced axonal outgrowth of hippocampal neurons by the inhibition of voltage-gated
Ca2+ influx (Li et al., 2017). The previous effects support the potential use of PRE-084 in
neurological diseases such as motor and cognitive dysfunction or stroke and brain injury
as follows:
PRE-084 and motor function:
There are many examples for usage of PRE-084 as neuro-protective in disease
models. In a mouse mode of spinal muscular atrophy, Claudia Cervero et al found that
PRE-084 could prevent against central synapse loss of motor neurons and reactive
microglial cell activation with restoration of M1/M2 balance that was changed in the
disease phenotype. However, these beneficial effects were not sufficient to restore
motor neuron degeneration and motor functions in those mice(Cervero et al., 2018).
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In a mouse model of parkinsonism, PRE-084 significantly improved spontaneous
forelimb use that was accompanied by increased density of dopaminergic fibers in the
most denervated striatal regions, by a modest recovery of dopamine levels, and by an
upregulation of neurotrophic factors (BDNF and GDNF) and their downstream effector
pathways (extracellular signal regulated kinases 1/2 and Akt)(Francardo et al., 2014).
PRE-084 has also been beneficial in Amyotrophic Lateral Sclerosis (ALS)
(Lengfeld et al.) by improving locomotor function and motor neuron survival in pre
symptomatic and early symptomatic mutant SOD1-G93A mice (ALS mice)(Peviani et
al., 2014). Mancuso et al further investigated the protective effects of PRE-084 in ALS
mice(Mancuso et al., 2012). They showed that PRE-084 improved motor function and
motor neuron survival in ALS mice. PRE-084 also extended survival in both female and
male mice by more than 15 %(Mancuso et al., 2012). The mechanisms were attributed
to induction of protein kinase C-specific phosphorylation of the NR1 subunit of the Nmethyl-D-aspartate (NMDA) receptor and a reduction of the microglial reactivity
compared with untreated mice(Mancuso et al., 2012). Collectively, they suggest the
potential therapeutic use of sigma agonists such as such as PRE-084 in ALS. Penas et
al reported that Pre-084 increased GDNF and BiP expression and promoted
neuroprotection after root avulsion injury(Penas et al., 2011). Furthermore, PRE-084
attenuated head twitch response in mice caused by 2,5-dimethoxy-4-iodoamphetamine
(DOI)(Malik et al., 2016).
PRE-084 and cognitive disorders:
PRE-084 could ameliorate anxiety like behavior and cognitive impairments in a rat
model of post-traumatic stress disorder through BDNF,TrkB-ERK signaling pathway (Ji
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et al., 2016). Moreover, PRE-084 attenuated the learning and memory loss in brain
ischemia/reperfusion induced vascular dementia model possibly through NR2ACaMKIV-TORC1 pathway(Xu et al., 2015). In addition, σ1 agonism has been shown to
alleviate blood brain barrier dysfunction in a vascular dementia mouse model(Liu et al.,
2018). In an Alzheimer disease mouse model, PRE-084 protected mitochondrial
respiration(Lahmy et al., 2014). PRE-084 abolished the inhibitory effect of amyloid β on
long term potentiation, suggesting its role in Alzheimer disease(Solntseva et al., 2014).
PRE-084 was also recognized as a precognitive compound that promotes neurite
growth(Page et al., 2015). PRE-084 was found to protect against glutamate induced
excitotoxicity in primary hippocampal neurons(Griesmaier et al., 2012)
Hyrskyluoto et al have targeted PRE-084 as a therapeutic in Huntington disease
where they showed that it could increase cell survival and counteract the deleterious
effects caused by N-terminal mutant huntingtin proteins in neuronal PC6.3 cells.
Specifically, PRE-084 increased cellular antioxidants by activating the NF-κB pathway
that is compromised by the mutant huntingtin proteins suggesting the future use of
sigma agonists in Huntington disease(Hyrskyluoto et al., 2013).
PRE-084 has been used as antidepressant in preclinical depression
models(Skuza & Rogoz, 2009; Villard et al., 2011).
Impact of PRE-084 on stroke and brain injury:
PRE-084 has been suggested to have neuroprotective effects against excitotoxic
perinatal brain injury in newborn mice as it was shown that PRE-084 treatment
decreased cell death as indicated by reduced TUNEL positivity and caspase-3
activation a long with lowering the number of isolectin B4-positive and activated
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microglial cells (Griesmaier et al., 2012). Regarding stroke and ischemia/reperfusion
injury, σ1 receptor ligand PRE-084 reduced infarct volume, neurological deficits, proinflammatory cytokines and enhanced anti-inflammatory cytokines after embolic stroke
in rats(Allahtavakoli & Jarrott, 2011). This finding was consistent with the use of other
sigma agonists in stroke in middle cerebral artery occlusion rat model by Cuevas et
al(Katnik et al., 2014; Katnik et al., 2016; Behensky et al., 2019). PRE-084 was also
reported to protect against endoplasmic reticulum stress-mediated apoptosis in mice
with cerebral ischemia/reperfusion injury (Zhao et al., 2019). This protective effect was
confirmed in another study where they indicated the possible involvement of NR2Ainduced pathway to regulate brain-derived neurotrophic factor(Xu et al., 2017).
Stimulation of σ1 with PRE-084 was also shown to be involved in innate and adaptive
immune response(Szabo et al., 2014). Another study showed that PRE-084 reduced
infarct volume, neurological deficits, pro-inflammatory cytokines and enhanced antiinflammatory cytokines after embolic stroke in rats(Allahtavakoli & Jarrott, 2011).
PRE-084 and nociception:
By usage of PRE-084, a recent study has suggested the contribution of σ1 to
peripheral neuropathy in type 1 diabetes by enhancement of high mobility group box 1
protein (HMGB1) in dorsal root ganglia(Wang et al., 2018b). Another study has shown
the involvement of σ1 in hyperalgesia induced by chronic constriction injury in
rats(Espinosa-Juarez et al., 2017). In a mouse model, Tejada et al used PRE-084 to
confirm the involvement of σ1 receptors in inflammatory pain as they described σ1
receptors as a biological brake to immune-driven opioid analgesia during inflammatory
conditions in which immune cells and other sources of algogenic chemicals promote
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inflammatory pain, an effect that could be reversed by σ1 antagonists, suggesting the
possible usage of σ1 antagonists as a treatment of inflammatory pain.(Tejada et al.,
2014; Tejada et al., 2017). Moreover, PRE-084 could fully abolish the antinociception
caused by phenazocine enantiomers in mice in paw pressure nociception
test(Prezzavento et al., 2017). Entrena et al have found that σ1 activation by PRE-084
can promote mechanical allodynia after capsaicin nociception(Entrena et al., 2016). In a
rodent model of hindlimb thrombus-induced ischaemic pain, PRE-084 could induce
mechanical allodynia not by sole administration but when co-administered with acidic
pH solution suggesting that σ1 receptors may be involved in ischemic pain sensation by
modulation of acid sensing ion channels(Kwon et al., 2016). PRE-084 caused
nociceptive activation of trigeminal nucleus caudalis in rats suggesting its effects on
migraine(Pyun et al., 2014). It also enhanced mechanical allodynia by phosphorylation
of MAPK p38 in mice and neuropathic rats(Choi et al., 2013; Moon et al., 2013). PRE084 also attenuated morphine induced anti nociception(Sanchez-Fernandez et al.,
2013). σ1 receptors were proven essential for capsaicin-induced mechanical
hypersensitivity(Entrena et al., 2009). Choi et al used PRE-084 to further confirm the
involvement of σ1 in hypersensitivity in mice (Choi et al., 2016a). Another study showed
the contribution of σ1 to mechanical allodynia in spinal cord injured mice(Choi et al.,
2016b). PRE-084 also induced neuropathic pain in rodents(Roh et al., 2008). Table 1
summarizes some of the applications of PRE-084 in the last few years with the
appropriate doses/concentrations that were used.
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Sigma-1 Receptor as cardioprotective.
Sigma-1 recxeptors have been proven important for cardiovascular health. A
recent study by Abdullah et al has shown that σ1 knock out mice had cardiac
dysfunction that was associated with impairment of mitochondrial dynamics and
bioenergetics(Abdullah et al., 2018). Another study has shown that the σ1 agonist
afobazole is cardio-protective in heart failure(Kryzhanovskii et al., 2018). Gao et al has
shown that σ1 agonism with PRE-084 is protective against ischemia/ reperfusion injury
in rats(Gao et al., 2018)

Other mechanistic effects:
PRE-084 has been shown to inhibit catecholamine secretion from adrenal
chromaffin cells by blocking nicotinic acetylcholine receptors(Brindley et al., 2017). It
also negatively affect N-type calcium channels in human embryonic kindney (HEK 293)
cells(Zhang et al., 2017). Another study has shown that PRE-084 can ameliorate
menadione- induced DNA damage of bone marrow cells extracted from CD1
mice(Voronin & Kadnikov, 2016). Hong et al have shown that PRE-084 and other σ1
agonists could facilitate the interaction between σ1 receptors and dopamine receptors
that stabilizes a conformational change in dopamine receptors to facilitate dopamine
binding(Hong et al., 2017) along with enhancement of dopamine levels(Garces-Ramirez
et al., 2011). PRE-084 could inhibit the osmotic swelling of Müller cell somata induced
by superfusion of rat retinal slices with a hypoosmotic solution by glutamatergic
stimulation(Vogler et al., 2016). PRE-084 also increased the expression of NMDA
receptors in rat hippocampus(Zhang et al., 2011; Pabba et al., 2014).
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Summary
Several lines of investigation suggest diverse potential therapeutic uses of σ1
agonists. In this review, we included some of the recent usages of PRE-084 in different
disease models including but not limited to enhancement of motor & cognitive functions
in neurodegenerative diseases, cardioprotection and nociception as summarized in Fig.
3. Most of research projects studied σ1 receptor functions focused on brain and
neurological functions. However, taking into consideration σ1 expression levels in other
tissues summarized in figure 1, it is noticed that σ1 expression other organs, for
example liver, blood vessels, bladder and fibroblasts is shown to be higher than brain
expression levels. Suggesting new avenues for investigating functional significance of
σ1 in these tissues. Not shown in this figure, expression of σ1 in lymphatic vessels has
been previously documented and proven to impact lymphatic diameter(Trujillo et al.,
2017). This will suggest the potential use of PRE-084 in other models.

1 e. Innovation, Gap in Knowledge and purpose of the dissertation.
It was previously reported that Sigma-1 receptor can influence NO production in
lymphatic endothelial cells causing lymphatic relaxation. It was also shown that Sigma-1
can maintain blood brain barrier integrity. Since endothelium is a main component of
BBB, we wanted to specifically test the potential endothelial protective roles of sigma-1
in endothelium. We wanted to address the gap in knowledge pertaining to identification
of endothelial specific mechanisms of actions of sigma-1 and link its action on nitric
oxide production and barrier enhancement to get a better understanding on how σ1 acts
in endothelial cells.
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Another gap in knowledge is that σ1 has been proven effective on modulation of
energetic profile in some models such as the heart muscle. Its close proximity to
mitochondria suggests its ability to influence energy production. However, its role in this
aspect in endothelial cells haven’t been previously elucidated in detail. We aim to
investigate endothelial protective roles of σ1 regarding NO production, barrier protection
and energy stabilization. Understanding the basic mechanisms of action of σ1 will open
new horizons and lines of investigation of σ1 as a therapeutic target in cases involving
endothelial dysfunction or insufficient energy production.
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1.f Figures:

Figure 1. Gene expression level of σ1 in different human tissues.
Data obtained from GTex portal database, GTEx Analysis Release V8 (dbGaP
Accession phs000424.v8.p2). Gene code ID (ENSG00000147955.16), location
chr9:34634722-34637809. Date accessed November 18th, 2019. Gene description:
sigma non-opioid intracellular receptor 1 [Source:HGNC Symbol;Acc:HGNC:8157]. The
x axis shows different tissues tested. The y-axis represents transcripts per million
(TPM). Number of examined samples for each tissue ranges from n=4 (kidney: medulla)
to n=803 (skeletal muscle).
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Table 1

Application

Organism

Dose

Author

1

Improved NGF-induced neurite outgrowth
inhibition by DEX

1 µM for 24 h

2

Didn't affect HIV Infectivity

PC12 cells (rat
pheochromocytom
a)
Macrophages

1 µM or 10 uM

3

Prevent Central Synapse loss

mice

0.25 mg/kg/day

4

Ameliorates Myocardial Ischemia-Reperfusion

rats

1 mg/kg

5

Involved in the development of diabetic
neuropathic pain
Meth leads to neural apoptosis, which might
be partially channeled through the sig‐1R
Restored synaptic connections between the
cortical and striatal neurons

mice

0.6 µM

neurons

20 µM for 1 hour

corticostriatal
culture

100 nM

hippocampal
neurons
adrenal chromaffin
cells

10 µmol/L

Matsushima
, Yukari,
2018
Omar Vélez
López, 2018
Clàudia
Cerveró,
2018
Qi-Jun Gao,
2018
XiaoleiWan
g, 2018
Jingying
Zhu, 2018
A. V.
Bol’shakova
, 2017
Dong Li,
2017
Rebecca L.
Brindley,
2017
VedranaTad
ić, 2017
Josué Vidal
Espinosa‐
Juárez,
2017
Kang
Zhang,
2017
L. Saulite,
2017
Mikhail V.
Voronin,
2016
J. M.
Entrena,
2016
E
Griesmaier,
2014
Katnik, 2006

6
7
8

Increases axon outgrowth

9

Inhibit catecholamine secretion

10

Modifies intracellular calcium

Motor neurons

10 µM

11

Decreases Hyperalgesia

rats

100 µM

12

Negative Modulation on N-type Calcium
Channel

Brain slices

50 µM

13

Differentiation into schwann cells

14

Cytoprotective

skin mesenchymal
cells
bone marrow

0.3-3 µM, up tp 200
µM
1, 10 µM/liter

15

Promotes Mechanical Allodynia

mice

32mg/kg

16

Protects against glutamate induced
excitotoxicity

Hippocampal
Neurons

10 or 100 µM

17

Decreases Calcium

Neurons

10 or 100 µM

5 µM , 10 µM

Different application and doses/concentrations of PRE-084 in different disease
models.
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Figure 2. Chemical Structure of PRE-084.
2-(4-Morpholino)ethyl-1-phenylcyclohexane-1-carboxylate. The active site is the
arylcycloalkalyl group, the amine group and the intermediate chain while the phenyl
group remains inactive.
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PRE-084
Cardio-protec4on
Brain
• Spinal Muscular Atrophy
• Neurite Outgrowth
• Post trauma4c stress
disorder
• Head Twitch response
• Vascular Demen4a
• Alzheimer
• Parkinsonism
• Amyotrophic lateral
sclerosis
• Hun4ngton Disease
• Perinatal Brain Injury
• embolic stroke
• Root Avulsion Injury

Nocicep4on

Heart

• Peripheral Neuropathy
• Chronic Constric4on Injury
• Inﬂammatory pain
• Capsacin nocicep4on
• Ischemic pain
• Migraine
• Neuropathic Pain

• Myocardial Ischemia
Reperfusion Injury
• Myocardial Infarc4on

Other mechanis4c
eﬀects
• Inhibits catecholamine secre4on
from adrenal chromaﬃn cells
• Nega4vely aﬀect N-type calcium
channels in human embryonic
kidney
• Ameliorate menadione- induced
DNA damage
• Facilitate the interac4on between
σ1 receptors and dopamine
receptors
• Inhibit the osmo4c swelling of
Müller cell somata induced by
superfusion of rat re4nal slice
• Increased the expression of NMDA
receptors
• An4depressant
• Alleviates blood-brain barrier
dysfunc4on in vascular demen4a
mice.

Figure 3. Summary of uses and applications of PRE-084 in disease models.
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Chapter Two
Materials and Methods
2 a. Materials
Animal Care and Use:
All procedures were approved by the Institutional Animal Care and Use
Committee of the University of South Florida under protocol number IS00002179. The
experiments were performed in accordance with the National Institutes of Health Guide
for the Care and Use of Laboratory Animals (8th ed., 2011) and are reported here in
accordance with the Animal Research: Reporting of ex Vivo Experiments guidelines.
Sprague-Dawley rats (5–9 wk of age) were purchased from Charles River (Wilmington,
MA) and housed in a temperature (22°C)- and illumination (12:12-h light-dark cycle)controlled environment. After arrival, rats were allowed to acclimate for 1 wk; standard
rat chow (2018 Teklad Global 18% Protein Rodent Diet, Harlan, Indianapolis, IN) and
water were provided ad libitum. All possible measures were taken to minimize pain or
suffering, including administration of general anesthesia by isofluran inhalationbefore
the experiments. All rats were euthanized by extension of the laparotomy into the chest
cavity and injection of Euthasol/SomnaSol (0.1 ml/450 g body wt) directly into the
cardiac ventricle, in accordance with American Veterinary Medical Association
guidelines for the euthanasia of animals.
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Human Tissue was obtained from LifeLink tissue bank through molecular
pharmacology and physiology department in a sealed container with a physiological
solution. Tissue was completely unidentified.
Components of Albumin Physiological Salt Solution:
Ringer Stock (NaCl, 600 mM; KCl, 23.5 mM; MgSO4 7H2O, 5.8 mM and CaCl2
2H2O, 10 mM); MOPS buffer 3 mM; NaH2PO4.H2O 2.1 mM; Na pyruvate 2.0 mM;
EDTA 0.02 mM; Glucose 5.0 mM; Albumin (bovine) 10g/1L. Crystallized bovine albumin
(purified BSA; Fisher Scientific), used for preparing physiological salt solutions, was
from Affymetrix (Santa Clara, CA). Other components were from Sigma-Aldrich (St.
Louis, MO, USA).
4-Amino-5-methylamino-2′,7′-difluorofluorescein diacetate (DAF-FM; catalog
no. D23844) was from Life Technologies (Carlsbad, CA). Human Brain Microvascular
endothelial cells were purchased from ScienCell (Carlsbad, Ca). Human Umbilical Vein
endothelial cells and Human dermal microvascular endothelial cells were from Lifeline
cell Technologies. Human lung endothelial cells were from Lonza and human dermal
lymphatic endothelial cells were from Lifeline cell technologies. Growth media with
supplementary life factor kit were from lifeline cell technologies. For florescent imaging
we used ASI imaging system. Antibodies: p-eNOS s1177, total eNOS, p-AKT s473, total
AKT, from cell signaling technologies. PECAM-1 antibody was from abcam.VECadherin antibody fisher scientific, ZO-1 antibody was from Invitrogen (Carlsbad, CA),
β-catenin antibody was from cell signaling technologies. Sigma-1 antibody from Novus
Bio. Gels, running buffer and transfer buffer were from NuPage fischer scientific.

26

Afobazole was generously provided by IBC Genarium (Moscow, Russia). BD
1047, PRE-084, DTG, SA-4503 were purchased from Tocris Bio. Sigma-1 siRNA, Non
Targeting RNA were from Dharmacon. Simple western (WES) supplies were provided
though protein simple, a biotechne brand. ECIS 96 well plates 20idf were purchased
from Applied Biophysics. IL-1β was supplied through enzo, CCCP was purchased from
abcam. Seahorse supplies were purchased from Agilent technologies.

2 b. Cell Culture and electroporation:
HUVEC, HDMEC, HLEC, HDLEC were routinely grown in lifeline growth medium
in 1.5% gelatin-coated culture dishes. For all studies, passage 1-5 cells were used. For
transfection, cells grown to 80% confluence were trypsinized and pelleted, and 5 X 105
cells were resuspended in 100 µl electroporation master mix containing either 2 µg
plasmids or 200 nM siRNA. This mixture was transferred to a cuvette for transfection
using a Nucleofector II system (Lonza, Basel, Switzerland) with program A-034
(HUVEC) or T-030 (HDLEC). Warm Lifeline

(500 µl) was added into the cuvette

immediately after electroporation. Cells were later distributed evenly onto gelatin-coated
35-mm dishes for protein extraction, gelatin-coated MatTek 35-mm #1 glass bottom
dishes for time-lapse microscopy, or 96W20E ECIS arrays (Applied Biophysics, Troy,
NY) for determination of barrier function.

2 c. Western Blotting:
Cell protein lysates were obtained as previously described(Breslin et al., 2015b).
Protein levels were quantified with the BCA protein assay kit (Thermo Scientific,
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Rockford, IL). Protein (15 µg) was mixed with NuPAGE® Reducing agent containing
NuPAGE® LDS sample buffer (Invitrogen, Carlsbad, CA), heated at 70 °C for 10 min,
and loaded into Novex® 4-12% Bis-Tris precast gels (Invitrogen, Carlsbad, CA) for SDSPAGE. Proteins were transferred onto 0.45 µm PVDF membrane and blocked with 5%
BSA in TBST (20 mM Tris-HCl, PH 7.6, 150mM NaCl, 0.1% Tween 20). Membranes
were incubated with primary antibodies at 4 °C overnight, and washed three times in
TBST. Afterwards, secondary antibodies were applied at room temperature for 1 h,
followed by three washes with TBST. Bands were visualized with Supersignal® HRP
substrate (Thermo Scientific, Rockford, IL) and imaged with Bio-Rad Gel Doc™ system
(Bio-Rad, Hercules, CA).
For some experiments, automated western blotting using Simple Western (WES)
was used according to manufacturer’s instructions. Sample concentration of 0.2 mg/ml
was used based on prior titration. Primary antibodies were used at 1:50 dilution. The
primary antibodies used were: Rabbit polyclonal anti sigma-1R NBP1-82479 from
NovusBio (Centennial, CO, USA), mouse monoclonal anti β-actin #3700 from cell
signaling technology (Boston, MA, USA). Anti rabbit and anti mouse secondary
antibodies were supplied with WES detection module kits from Protein Simple and the
manufacturer’s compass software was used for data analysis.

2 d. Isolated Arteriole Preparation:
Parenchymal arterioles were isolated from brains of Sprague-Dawley rats and
mounted onto glass micropipettes in a 37 °C bath containing albumin-physiological salt
solution. The nonselective σ agonist afobazole was applied to the bath at
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concentrations of 50, 100, 150, 200, and 250 µM in the presence or absence of the σ1
antagonist BD1047.
Sprague-Dawley rats were euthanized by carbon dioxide overdose and
decapitated. For each rat, the brain was removed, taking care to preserve the ventral
vascular network. The brain was kept in albumin physiological salt solution (APSS) on
ice then it was put on a silicone-coated plate filled with cold APSS. The brain was
pinned to the silicone with Circle of Willis facing upwards. Under a dissecting
microscope, the middle cerebral artery was dissected along with its branching arterioles.
An unbranched parenchymal arteriole was selected and cannulated onto glass
micropipettes. Pressure was increased from 0 mmHg to 50 mmHg using a wall-mounted
manometer connected to the cannula, and temperature was held at 37° C. The arteriole
was left to equilibrate and develop a resting tone for 30 minutes before adding different
treatments. At the end of the experiment, calcium-free solution was added to achieve
the maximum diameter of the arteriole followed by APSS with calcium to return the
vessel to its original diameter, which demonstrated viability. Arteriolar diameter was
measured by a Living Systems video caliper connected to a computer running iWorks
software.

2 e. Nitric Oxide Measurement:
Changes in NO concentrations were measured in endothelial cells using
fluorescence imaging techniques and the NO-sensitive dye DAF-FM. Cells were loaded
using membrane-permeable DAF-FM. Cells seeded on coverslips were incubated for 1
h at 37°C in HBSS (135 mM NaCl, 5 mM KCl, 1.5 mM CaCl2, 1 mM MgCl2, 10 mM
glucose, and 10 mM HEPES, pH 7.4) with 8 µM DAF-FM and 0.8% DMSO. Coverslips
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were washed in DAF-FM-free HBSS before experiments were performed. Cells were
illuminated with 495-nm light for 400 ms at 0.3 Hz (Lambda DG-4, Sutter Instruments,
Novato CA), and fluorescence emissions at 535 nm were collected using a digital
charge-coupled device camera (Sensicam, Cooke, Auburn Hills, MI). Imaged cells were
perfused with control solution and solutions containing 300 µM afobazole, using a
perfusion system consisting of 250-µm-diameter glass tubes positioned 500 µm away
with flow rates of 300 µl/min.

2 f. Seahorse Assays:
We used Seahorse xfp analyzer system from Agilent (Santa Clara, CA, USA) for
our bio-energetic measurements. Glycolytic rate assay, cell mito-stress test and ATP
rate assays were used. All protocols were done according to manufacturer’s
instructions. Briefly, HUVEC or HDLEC cells were seeded onto Seahorse cell culture 8
well plates at a density of 40,000 cells/well (for HUVEC) and 30,000 cells/well (for
HDLEC) the day before experiment. The following day, media was changed to
Seahorse medium containing glucose, glutamine and pyruvate as well as HEPES buffer
and cells were incubated in a non-CO2 incubator for 1 hour before the experiment.
Seahorse measures glycolytic rates and ATP production rates using Extracellular
Acidification Rates (ECAR) and Oxygen Consumption Rate (OCR) measurements. For
cell mitostress test, cells were left to obtain a baseline reading before injection of
oligomycin (1µM), FCCP (1µM) and lastly Rot/AA mixture (0.5 µM) and the software
uses the obtained ECAR and OCR values to generate the assay readouts.
Glycolytic rate assay measurement depends on the fact that glucose is converted
to pyruvate and lactate in cytoplasm or CO2 and water in mitochondria. Conversion of
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glucose to lactate results in proton production in the assay medium. The assay workflow
is as following, baseline recordings of OCR and ECAR are obtained for around 20 min
then Rotenone/Antimycin A mix at a concentration of 0.5 µM is injected to inhibit oxygen
consumption and CO2 derived protons. Then 2-Deoxy-Glucose (an inhibitor of
glycolysis) is injected at a concentration of 50 mM to confirm that the measurements of
proton efflux rate prior to the injection is due to glycolysis.
Similar procedures were used to measure ATP production rates. Baseline
measurements of ECAR and OCR were obtained followed by injection of 1.5 µM of
oligomycin then 0.5 µM of Rot/AA. In cells, both glycolysis and oxidative
phosphorylation contribute to extracellular proton extrusion, therefore seahorse
measures ATP production rates using equations involving both ECAR and OCR. Data
were obtained from wave software and seahorse report generators. Adapted from:
White paper: Quantifying Cellular ATP Production Rate Using Agilent Seahorse XF
Technology, ATP Production Rate Calculation using the system built in measurements
was as follows: depending on the fact that during conversion of
one molecule of glucose to lactate in the glycolytic pathways, 2 molecules of each ATP,
H+, and lactate are
produced (Eq. 1).
Glucose + 2 ADP + 2 Pi ➔ 2 Lactate + 2 ATP + 2 H2O + 2 H+ (Eq. 1)
Glycolytic ATP production rate which is equivalent to Glycolytic Proton Efflux,
glycoPER, (Eq. 1) can be calculated as:
glycoATP Production Rate (pmol ATP/min) = glycoPER (pmol H+/min) (Eq. 2)
glycoPER (pmol H+/min) = PER (pmol H+/min) – mitoPER (pmol H+/min) (Eq. 3)
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PER (pmol H+/min) = ECAR (mpH/min) x BF (mmol H+/L/pH) x Vol XF microchamber
(µL) x Kvol (Eq. 4)
mitoPER (pmol H+/min) = mitoOCR (pmol O2/min) x CCF (pmol H+/pmol O2) (Eq. 5)
mitoOCR (pmol O2/min) = OCR basal (pmol O2/min) – OCR (Rot/AA) (pmol O2
/min) (Eq. 6)
Where BF (Eq. 4) represents buffer factor - the buffering capacity of the system
(including buffer capacity of the assay media and XF assay conditions) buffer factor
value was 2.5, CCF (Eq. 5) is the CO2 Contribution Factor and has value of 0.50 and
Kvol (Eq. 4) has value of 1.1.
The rate of oxygen consumption that is coupled to ATP production during OXPHOS can
be calculated as the OCR that is inhibited by addition of oligomycin (ATP synthase
inhibitor) (Eq. 7).
OCR ATP (pmol O2/min) = OCR basal (pmol O2/min) – OCR Oligo (pmol O2/min) (Eq.
7)
To convert this rate of molecular oxygen consumption we need to multiply by 2 (to
convert to O atoms) and by the P/O ratio, the number of molecules of ATP synthesized
per atom of O reduced by an electron pair (Eq. 8):
mitoATP Production Rate (pmol ATP/min) = OCRATP (pmol O2/min) * 2 (pmol O/pmol
O2
) * P/O (pmol ATP/pmol O) (Eq. 8)
Theoretical P/O ratio values were previously estimated considering the stoichiometry of
each metabolic fuel, combined with experimental results obtained using isolated
mitochondria and considering F1 F0
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Finally, the total cellular ATP Production Rate is the sum of the glycolytic and
mitochondrial ATP Production Rates:
ATP Production Rate (pmol ATP/min) = glycoATP Production Rate (pmol ATP/min) +
mitoATP
Production Rate (pmol ATP/min) (Eq. 9)

2 g. In vitro endothelial barrier measurements
Transendothelial electrical resistance (TER), which is an index of barrier function
of cultured endothelial cell monolayers, was measured with an Electrical Cell-Substrate
Impedance Sensor (ECIS) ΖΘ System (Applied Biophysics, Troy, NY). Cells were
seeded into gelatin-coated wells of ECIS arrays (96W20E) and allowed to attach
overnight in lifeline complete vasculife media to form a confluent monolayer. The next
day, medium was changed to VBM at least 1 h before the experiment. A 1-µA AC signal
at 4 kHz was applied. Total impedance was measured by monitoring the voltage across
the electrodes. Impedance data was later converted into monolayer resistance and
capacitance,

respectively

representing

barrier

function

and

membrane

capacitance(Giaever & Keese, 1993).

2 h. Human arteriole preparation:
The human mesenteric artery was removed and immediately placed in a chilled 4
solution buffer of the following composition: Ringer Stock (NaCl, 600 mM; KCl, 23.5
mM; MgSO4 7H2O, 5.8 mM and CaCl2 2H2O, 10 mM); MOPS buffer 3 mM;
NaH2PO4.H2O 2.1 mM; Na pyruvate 2.0 mM; EDTA 0.02 mM; Glucose 5.0 mM;
Albumin (bovine) 10g/1L. Tissues were cleaned from connective and adipose tissues
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and and the arteries were cut into rings (1 mm length) and mounted in a chamber wire
myograph (MYO-01, VT, USA) connected to a LabScrible2® data acquisition system
(software rev 1.1; IWorx, Dover, NH, USA). The bathing solution was maintained at
37°C and the tissues were allowed to equilibrate for 60 min under a resting tension of 45 mN. Cumulative concentration response curves to α1-adrenergic receptor agonist
phenylephrine (PHE; 1 nM to 100 µM) in basal tonus. Maximal contraction was
expressed as mean of the contraction in mN divided by weight of vascular tissue
(mN.mg-1). For relaxation response, cumulative concentration curves to NO donor
sodium nitroprusside (SNP; 1 nM to 10 µM) were obtained in PHE-contracted rings.
Relaxation was evaluated only in rings that reached a plateau after PHE-induced
contraction. Vascular relaxation was expressed as the percentage of PHE-induced
maximum contraction. Both protocols (contraction and relaxation response) were
constructed in the absence and presence of agonist of the σ receptor with selectivity for
the σ1 subtype, PRE084 (100 µM) pre-incubated by 30 min. Potency is given by the
pEC50, which represents the concentration of each drug necessary to cause 50% of
maximum relaxation or contraction, and it was expressed as –log molar (M). PHE and
SNP were purchased from Sigma-Aldrich (St Louis, MO, USA). All other reagents used
were of analytical grade. Stock solutions were prepared in deionized water and stored in
aliquots at –20°C; dilutions were made up immediately before use.
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Chapter Three:
Sigma-1 agonists modulate arteriolar diameter and
eNOS activity
3a. Introduction
Several reports suggest that σ1 activation improves outcomes following stroke
injury(Katnik et al., 2014). Previously identified mechanisms include preserving calcium
homeostasis and glial cell function, lowering infarct volume(Cuevas et al., 2011; Katnik
et al., 2016). Our recent study shows that σ1 agonism by afobazole relaxes rat
mesenteric lymphatic vessels (Trujillo et al., 2017). The response was attenuated by the
NO synthase inhibitor L-NAME. Furthermore, afobazole was shown to elicit elevated
NO production in cultured lymphatic endothelial cells (Trujillo et al., 2017). Other studies
have also suggested the potential link between σ1 an eNOS. Bhuiyan et al have
demonstrated that σ1 agonism by DHEA treatment induces stimulation of Akt-eNOS
signaling pathways in rat thoracic aorta (Bhuiyan et al., 2011). They have also shown
that σ1 activation protects against hypertension-induced kidney injury by stimulation of
Akt-eNOS signaling pathway (Bhuiyan & Fukunaga, 2010).
Our laboratory has shown that afobazole which has σ1 agonist properties, could
change tone and contraction of lymphatic vessels a long with enhancement of nitric
oxide production from lymphatic endothelial cells(Trujillo et al., 2017). However, there is
lack of studies regarding the mechanisms of σ1 agonist induced NO production in
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endothelial cells. The objective of this study is to investigate the contribution of σ1 in
eNOS activation and vasodilation involving the mechanisms by which σ1 activation
elicits eNOS mediated NO production. To attain this objective we tested our working
hypothesis that σ1 receptor stimulation activates eNOS to enhance endothelial NO
production that leads to arteriolar dilatation and improves blood flow. We performed
eNOS quantifications in endothelial cells in different conditions as well as ex vivo
models of isolated rat brain parenchymal arterioles. The rationale for this study was to
contribute a missing element in our knowledge of how σ1 receptor activation contributes
to endothelial NO production as a potential mechanism of arteriolar dilatation, which
could increase blood flow and enhance endothelial health. This contribution is vital for
the development of new therapeutic strategies to promote endothelial health based on
σ1 activation aiming at blood flow improvement in some diseases.

3b. Results
3b.i. Effect of Afobazole on Isolated Rat Brain Arteriolar Diameter:
To measure the impact of afobazole on vessel diameter, parenchymal arterioles
were isolated from brains of Sprague-Dawley rats and mounted onto glass
micropipettes in a 37 °C albumin-physiological salt solution bath, and pressurized at 2
cm H2O. Afobazole could significantly enhance the diameter of isolated rat brain
arterioles when applied at 150 µM, 200 µM, 250 µM (Figure 4, A,B). The presence of
BD 1047 significantly attenuated PRE-084 induced arteriolar dilation (Figure 4. D).
Notably, there was no difference between males and females in terms of arteriolar

36

dilation (Figure 4. C). The results indicate that σ1 activation by afobazole can decrease
arteriolar tone which could enhance blood flow in certain disease models.
3b.ii. Impact of afobazole on NO production from Brain Endothelial Cells:
We next wanted to elucidate the mechanism of arteriolar dilation and blood flow
enhancement. Due to our previous finding of the enhancement of lymphatic endothelial
NO production using afobazole, we wanted to see whether the same mechanism
extends to blood endothelial cell. Brain endothelial cells were chosen for this study.
Using DAF-FM we were able to assess the change in NO level following afobazole
treatment. The intensity of the florescence signal indicates the more NO being produced
which is represented by the change in the slope in the shown trace. Concentration of
300 µM caused significant enhancement of NO production (Figure 5).
3b.iv. eNOS phosphorylation in response to afobazole in HBMEC:
Based on the findings from our previous paper regarding enhancement of
lymphatic NO production with afobazole(Trujillo et al., 2017) and the previous shown
results of arteriolar tone modulation σ1 agonism, experiments were carried out to
determine whether NO production also involves enhancement of eNOS phosphorylation
at s1177 which is the activation site(Fulton et al., 1999). HBMECs were treated with
afobazole 300 µM or vehicle for 2 minutes. Afobazole caused a significant elevation of
eNOS phosphorylation in HBMEC (Figure 6).
3b.v. Sigma-1 and eNOS subcellular location:
After noticing the link between sigma-1 activation and eNOS activation, we were
interested to look at their subcellular localization. We did immunofluorescence staining

37

of eNOS and sigma-1 and noticed similarity of the localization peri-nuclear with
Pearson’s Coefficient of 0.25 indicating a possible co-localization (Figure 7).
3b.vi. PRE-084 effect on eNOS and AKT phosphorylation in HUVECs:
Because afobazole is a non selective sigma-1 agonist(Katnik et al., 2016), we
were interested in investigating the effects of σ1 receptor only without any influence on
σ2 as σ1 was the subtype found to be functional in lymphatic vessels and endothelium
(Trujillo et al., 2017). That’s why we chose to conduct the following experiments using
PRE-084 the selective σ1 agonist(Maurice, 2001). HUVECs were also chosen for the
subsequent experiments since HUVECs are proven to be a good model for endothelial
barrier in general to generalize our results. HUVECs have been used in many studies
targeting endothelial specific mechanisms(Adderley et al., 2015a; Adderley et al.,
2015b; Zhang et al., 2016a). Selection of the appropriate concentration to use PRE-084
was done based on a concentration response experiment where we used
concentrations of 1 µM, 10 µM, 100 µM. 100 µM showed significant increase in eNOS
phosphorylation at s1177 (Figure 8).
Next, we wanted to investigate the best time point to assess phosphorylation by
doing a time course of 100 µM PRE-084 treated cells at 30s, 1 min, 2 min, 5 min, 10
min. Experiments were done using simple western protein technology. At 10 min after
PRE-084 treatment we noticed significant increase in eNOS phosphorylation at s1177
(Figure 9, A) . Next we wanted to examine whether σ1 antagonism will have any effect
on eNOS activation. We used the σ1 antagonist BD1047 at 200 nM concentration which
was obtained from our previous study as this concentration could block afobazole
induced lymphatic dilation in our previous paper(Trujillo et al., 2017). We noticed that
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BD 1047 causes apparent decrease in eNOS phosphorylation p=0.06 even in the
absence of the agonist (Figure 9 B). So, we think it may an inverse agonist in this case.
The next step was to confirm that PRE-084 enhances eNOS phosphorylation by σ1
activation. This was done by pre-treating cells by BD1047 200 nM for 5 minutes before
adding PRE-084. As expected, the presence of BD 1047 attenuated PRE-084 induced
eNOS phosphorylation at s1177 (Figure 9 C), confirming the involvement of σ1
receptors in eNOS phosphorylation.
We next used our model of σ1 kd HUVEC cells to assess whether the deficiency
of σ1 causes decrease in eNOS phosphorylation by its own. We noticed that σ1 kd cells
had a similar amount of eNOS p-s1177 as the control cells indicating that the activation
of the receptor not just the presence causes the effect (Figure 10). Since our data show
that PRE-084 enhances eNOS activation, we wanted to look at AKT which is the
upstream signaling molecule of eNOS(Dimmeler et al., 1999). PRE-084 caused an
apparent increase in AKT phosphorylation at s473. However it was not statistically
significant (Figure 11). We also wanted to examine whether σ1 kd cells will have
different amount of p-AKT s473 than the control cells. Our σ1 kd had no significant
difference of the level of AKT p-s473 than compared to control (Figure 12).
3b. vii Sigma-1 is important for shear stress and PRE-084 induced eNOS
phosphorylation
We also wanted to examine the effects of PRE-084 in shear stress induced NO
production and whether the effect would be abolished in σ1 kd cells. Our results show
that PRE-084 enhanced eNOS phosphorylation in control cells not in σ1 kd. Also, shear
stress could elicit higher phosphorylation of eNOS at s1177 in control cells not in σ1 kd
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cells (Figure 13). Suggesting a potential role of σ1 in shear stress sensing and
mechano-transduction.

3b. viii PRE-084 effect on isolated human mesenteric rings:
We wanted to apply the previous concepts of sigma-1 induced blood vessel
diameter alteration in an ex vivo setting, specially, human tissue. Results show that
PRE-084 100 µM could decrease phenyl ephrine induced vasoconstriction (Figure 14)
and reduce sodium nitroprusside induced vasorelaxation (Figure 15).

Discussion and Conclusions
Consistent with the previous published findings that σ1 agonism activates eNOS
phosphorylation(Bhuiyan et al., 2011b, a; Gao et al., 2018) ,we also saw a similar effect
in HUVECs where sigma-1 agonism could enhance eNOS phosphorylation dose
dependently and time dependently (Figures 8,9). eNOS is an important regulator of
endothelial function that is necessary to maintain endothelial homeostasis(Heiss et al.,
2015). It is composed of two main domains, reductase and oxygenase. For activation, it
requires association with caveolae, calmodulin, L-arginine, tetrahydrobiopterin (BH4)
and phosphorylation at the activation site serine 1177(Davignon & Ganz, 2004). The
activation site s1177 was chosen as an indication of enzyme activity in our studies since
its assessment by protein assays has been obtained using applicable methods. eNOS
is expressed widely in endothelium of big vessels with its expression decreasing
towards microvasculature(Heiss et al., 2015). eNOS induced NO production has been
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proven endothelial protective by many mechanisms. eNOS knockout mice are
hypertensive, have poor vasorelaxing activity, increased neointimal proliferation, have
developmental growth problems, accelerated atherosclerotic lesions, abnormal aortic
valves and impaired endothelial dependent vasodilation in pulmonary
circulation(Albrecht et al., 2003). Impaired eNOS activity has been associated with
endothelial dysfunction(Huang, 2003).
Diseases that involve eNOS impairment include but not limited to hypertension,
diabetes, aging, and atherosclerosis(Huang, 2003). In this regard, efforts have been
made to restore eNOS expression or activate the already existing eNOS to counteract
or ameliorate such pathologies using several pharmacological modalities. While NO
donors have been tried to compensate insufficient eNOS activity(Hacker et al., 2001),
other studies have used eNOS gene transfer to effectively deliver eNOS to deficient
sites which was shown as a successful strategy in cases of hypertenstion, ischemia
reperfusion injury and atherosclerosis(Alexander et al., 1999; Ooboshi et al., 2000;
Abunasra et al., 2001). HMG co-A reductase and reducing LDL levels have been shown
to positively regulate eNOS activity(Blair et al., 1999). Also, estrogens are known to
activate eNOS by AKT dependent mechanism, which may explain the low incidence of
atherosclerotic diseases in pre-menopausal women(Laufs & Liao, 1998).
There is continuous need to develop drugs that can be beneficial in endothelial
dysfunction and eNOS impairment. Consistent with the previous finding by Bhuyian et al
that σ1 agonism by DHEA prevents decreases in aortic total eNOS levels in a pressureoverload heart failure model and also elevated eNOS p-s1177(Bhuiyan & Fukunaga,
2009), In our model of endothelial barrier using HBMEC, HUVECs, we found that two
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agonists of sigma-1; afobazole and PRE-084 could enhance phosphorylation of eNOS
at its activation site s1177. This suggests that it can be used as a therapeutic target in
diseases involving dysfunctional endothelium.
Another important finding is that σ1 kd cells didn’t upregulate eNOS p-s1177 in
response to shear stress. It was reported that in normal endothelial cells shear stress
activates eNOS and elicites NO production(Davis et al., 2004; Li et al., 2004), a
phenomenon that is necessary for auto regulation of blood flow and
vasodilation(Johnson, 1986; Paniagua et al., 2001). Our findings suggest a potential
role for σ1 in shear sensing. The key finding that σ1 agonism by afobazole could
increase rat brain arteriolar diameter suggests its potential roles as a therapeutic target
in cases involving brain blood flow impairment such as stroke. Especially because
afobazole has been tried in stroke rat models and shows enhancement of outcomes
even after delayed time points 48-72 hours following stroke(Katnik et al., 2014). This is
an advantage over tissue plasminogen activator (TPA), the only known drug to treat
stroke as TPA needs to be given within a very short time window 4-6 hours which is a
problem as patients normally get diagnosed after this window(Pena et al., 2017).
Our work suggests the potential use of other sigma-1 agonists such as PRE-084
as a drug to treat stroke in clinical trials after validation of the mechanisms in an animal
model.

42

Figures

Figure 4. Afobazole reduces arteriolar tone via Sigma-1R activation.
A. Example arteriolar diameter before and after addition of afobazole. B. Changes in
2+

arteriolar tone (% reduction in diameter compared to complete relaxation in Ca -free
bath) with increasing concentrations of afobazole. C. Potential sex differences in the
data. D. The σ antagonist BD1047 (200 nM) impairs afobazole-induced dilation.
1

*P<0.05 versus control by Dunnett’s test (panel B) or between groups by Fisher’s LSD
(panel D).

43

Figure 5. Afobazole enhances NO production in HBMEC.
Average tracing of fluorescence change from baseline of cultured brain endothelial cells
loaded with DAF-FM to detect NO production. Apparent elevation of NO was observed
shortly after afobazole 300 µM treatment. Analysis was done by ordinary one-way
ANOVA, Dunnett’s multiple comparison test. *P<0.05; N=5 HBMEC.
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eNOS p-s1177
Total eNOS

Figure 6. Afobazole enhances eNOS phosphorylation at s1177 in HBMEC.
Western blot analysis of cell lysates of HBMEC. Cells were treated with afobazole 300
µM or vehicle for 2 min. Significant increase of eNOS p-s1177/ total eNOS level was
observed as shown in the graph. Data represent mean ± SEM and analysis was done
using t-test. **P<0.01; N=6 for control group, N=5 for afobazole group.
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A

B

C

D

Figure 7. Immunofluorescence labeling of HBMEC monolayers.
The images show subcellular location of nuclei (blue; panel A) sigma-1 receptor (green;
panel B), eNOS p-s1177 (red; panel C) and their partial co-localization in a merged
image (yellow, panel D). The sigma-1 receptor is located mostly in perinuclear areas (B)
as is eNOS p-s1177, but with more density (C). White arrows show a representative
colocalization site (yellow dots in panel D). Images are representative of 4 experiments.
The averaged Pearson’s co-efficient was 0.25.
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Figure 8. PRE-084 enhances eNOS phosphorylation at s1177.
Western blot analysis of HUVEC cells treated with different concentrations of PRE-084.
100 µM caused a significant increase in eNOS p-s1177/ total eNOS. One-Way ANOVA
followed by Dunnett’s multiple comparison test used for analysis. P<0.05, n=3 each
group.
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Figure 9. Activation of σ1 elicits phosphorylation of eNOS on its activation site
A. Time-course of eNOS phosphorylation in HUVEC treated with the selective agonist
σ PRE-084 (100 uM ). *P<0.05 by Dunnett’s test for the 10-min treatment group vs.
1

control. N=4 for each group. B. The selective σ antagonist BD1047 (200 nM) inhibits
1

PRE-084-induced phosphorylation of eNOS. *P<0.05. N=12 control, N=8 PRE-084, N=8
BD-1047, N=3 PRE+BD 1047. Normalized peak area is eNOSp-s1177/ eNOS
expression.
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Figure 10. eNOS p-s1177 in σ1kd cells
Sigma-1 kd cells didn’t have a different amount of eNOS phosphorylation that control
cells. Cells were treated with either σ1 siRNA or non targeting RNA. Western blot shows
no difference between groups n=6 each group.
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Figure 11. Effect of PRE-084 on AKT phosphorylation in HUVECs
Cells were treated with PRE-084 100 µM for the shown time points. Western blot shows
apparent increase in AKT phosphorylation at s473, However, the bar graph showing
quantification indicates no statistical significance at 5 min. n=3/group.
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Figure 12. p-AKT S473 expression in σ1 kd cells.
Sigma-1 kd cells didn’t have a different amount of AKT phosphorylation that control
cells. Cells were treated with either σ1 siRNA or non targeting RNA. Western blot shows
no difference between groups n=6 each group.
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A

Figure 13. σ1 is important for PRE-084 and shear stress induced eNOS
phosphorylation at s1177.
A, Western blot of lysates of HUVEC cells treated with σ1 siRNA or non-targeting RNA
(NT) treated with PRE-084 100 µM or shear stress for 5 minutes. B, bar graph shows
decrease in response of σ1 kd cells to PRE-084 compared to control, N=1. C, bar graph
shows decrease in response of σ1 kd cells to shear stress compared to control, N=2.
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Figure 14. Effect of PRE-084 on phenyl ephrine induced human mesenteric arteriolar
contraction.
The α1-adrenoceptor agonist PHE (10-9 to 10-4 M) induced concentration-dependent mesenteric
artery contractions. The PRE084 promote a decrease of maximal responses (Emax) of PHE
when compared to the control. No significant differences in pEC50 for PHE were found between
groups. N= 5 per group.

53

Figure 15. Effect of PRE-084 on SNP induced human mesenteric arteriolar relaxation
The cumulative addition of NO donor, SNP (10-8 to 10-2 M) to PHE-contracted tissues (10-4 M)
produced concentration-dependent vascular relaxations. The PRE084 did not change the SNP
maximal response (Emax), but promote a decrease of pEC50 of SNP (P<0.05) when compared
to control. N=5/group.

54

Chapter Four:
Sigma-1 activation promotes endothelial barrier integrity
4a. Introduction
Endothelial barrier is an important characteristic of endothelium. Having as intact
endothelial barrier can help against some pathologies such as edema and ischemia
reperfusion injury(Aman et al., 2012). Due to our findings in previous chapter about
effects of σ1 on eNOS, we wanted to expand these findings trying to elucidate whether
eNOS activation and vasodilation will also be accompanied by barrier enhancement.
Some agents that cause vasodilation are reported to cause endothelial barrier
disruption and hyperpermeability. For example, histamine is known to cause
vasodilation and also disrupts endothelial barrier in vivo (Ashina et al., 2015). The well
known vasodilator nitroglycerin was reported to cause endothelial dysfunction by
adverse phosphorylation and S-Glutathionylation of eNOS(Knorr et al., 2011).
Moreover, the only approved drug to treat stroke tissue plasminogen activator was
shown to cause brain microvascular endothelial cell injury after oxygen and glucose
deprivation by inhibiting sonic hedgehog signaling(Gong et al., 2019). This might be the
cause of brain edema or angioedema of stroke patient treated with tPA(1989; Cheripelli
et al., 2016; Thoren et al., 2017; Zhao et al., 2017).
Given that σ1 has the potential to be administered in cases involving insufficient
blood flow in the previous chapter, we wanted to test the hypothesis that it also protects
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endothelial barrier which will give σ1 agonists an advantage over vasodilators that
cause endothelial injury making it safer with less side effects. The hypothesis is
supported by work by others showing that σ1 activation could protect against BBB
leakage in vascular dementia mice(Liu et al., 2018). This chapter will highlight our
proposed mechanisms of σ1 induced barrier protection that supports usage of σ1
agonists in disease models in line with what was shown in chapter three.

4b. Results:
4b.i. Assessment of σ1 kd cells response in ECIS:
In order to validate the contribution of σ1 to endothelial barrier function, we used
siRNA to selectively reduce σ1 expression in HUVEC. The behavior of σ1 knockdown
cells and non-targeting RNA transfected cells was compared with ECIS. Interestingly,
σ1 kd cells had significantly less TER than control cells (Figure 16.A). The difference
between the two groups was evident starting at 10 h post transfection and the TER of
σ1 kd cells continued to drop below control cells up to 70 h till the end of the experiment
(Figure 16 A). At 48-h and 70-h post-transfection with σ1 siRNA, Western blots show
47% and 74% decreases in σ1 protein, respectively, compared to controls. The degree
of σ1 siRNA knockdown correlates to significant decreases in TER in σ1 siRNA-treated
cells compared to control (Figure 16 C,D).
4b.ii. Junctional protein assessment in Sigma-1 knock down cells:
In order to explain the reason why σ1 kd cells had less TER, we hypothesized
that σ1kd cells may have different amount of junctional proteins either in total protein
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levels or junctional protein levels. Protein was collected from σ1 kd cells at 48 h or 72 h
post transfection. The level of σ1 protein was significantly reduced in σ1 kd cells as
expected. Interestingly, comparable deficiency of PECAM-1 levels was noticed in σ1 kd
cells compared to NT controls. Neither ZO-1 nor VE-Cadherin were changed at the total
protein level (Figure 17).

4b.iii. PRE-084 enhances endothelial barrier in HUVEC, HDMEC, HLEC, RBMEC:
The direct effects of σ1 agonism on endothelial barrier function of HUVEC was
evaluated using the highly selective σ1 agonist PRE-084 with ECIS. Different
concentrations of PRE-084 were applied (1µM , 5 µM, 10 µM, 50 µM, 100 µM, 150 µM,
200 µM). Choosing this range of concentrations was based upon the previously
published PRE-084 concentrations to be applied in cell culture in various models (Katnik
et al., 2006; Zhang et al., 2017; Lopez et al., 2018; Zhu et al., 2018). Consistent with the
previously reported protection of BBB with PRE-084(Liu et al., 2018), we saw a
concentration dependent increase in HUVEC barrier function indicated by TER
enhancement. The enhancement of TER started around 1 hour following application
and was sustained for 6 hours. Concentrations starting at 50 µM caused a significant
increase in barrier function compared to control group treated with equal volume of
media only at 3 hours. The maximum increase in TER was noticed at 100, 150, 200 µM
thus we chose 100 µM to pursue the following experiments (Figure 19). Similar effects
of PRE-084 in barrier enhancement were also noticed in other cell types HDMEC,
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HLEC (human lung microvascular endothelial cells), RBMEC with different time points
of TER enhancement with PRE-084 for each cell type (Figures 20,21,22).

4b.iv. BD 1047 effect on endothelial barrier:
HUVEC cells were treated with the sigma-1 antagonist BD1047 100 nM, 200 nM,
300 nM. The 300 nM concentration caused a time dependent decrease of TER that was
evident at 15 h in the absence of the agonist (Figure 23).

4b.v. PRE-084 doesn’t enhance TER in σ1 kd HUVEC cells:
Despite PRE-084 is a known highly selective σ1 agonist (Hyrskyluoto et al.,
2013), we wanted to confirm that the barrier enhancing effects that we saw in Figure 19
were only due to σ1 agonism not due to any non unknown specific binding. In order to
pursue this study, we wanted to evaluate the response of σ1 kd to PRE-084. We
assigned our cells into four groups, σ1 kd cells treated with vehicle control, σ1 kd cells
treated with PRE-084 100 µM, non targeting RNA transfected cells (NT) treated with
vehicle control or NT cells treated with PRE-084. Before the start of the experiment, we
noticed a significant difference between σ1 kd cells and NT control cells that the two
groups of σ1 kd cells had less TER than NT groups, a finding that was consistent with
the previous result . With analysis, we found that PRE-084 could enhance TER of NT
control cells not in σ1 kd cells (Figure 24). These results confirmed that PRE-084
enhances TER in HUVECs through σ1 agonism and σ1 is required for PRE-084
induced enhancement of barrier function.
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4b.vi. Impact Sigma-1 on IL-1β induced barrier disruption:
We next wanted to test whether the barrier enhancing properties of PRE-084
extends to counteracting barrier disrupting agents. Based on the previous finding that
PRE-084 causes slow but sustained barrier enhancement, we chose to challenge the
cells with a slowly acting barrier disrupter; IL-1β. IL-1β has been shown to disrupt barrier
function of endothelial cells(Du et al., 2015). The mechanisms have been previously
attributed to redistribution of junctional proteins via NF-KB pathway(Kimura et al., 2009).
As predicted, IL-1β (15 ng/mL) treatment significantly impaired TER starting at 2 hours
post treatment and continuing to decrease through the duration of the experiment. Pretreatment with PRE-084 significantly partially rescued IL-1β induced TER drop( Figure
25). After we noted the significant contribution of σ1 in maintenance of baseline barrier
function, we next wanted to challenge σ1 kd cells with IL-1β to compare their behavior
to control cells. σ1 kd cells had significantly worse barrier function (TER) in response to
IL-1β than control cells (Figure 25).

4b.vii. DTG increases TER in HUVEC:
DTG is another sigma-1 agonist(Shimizu et al., 2000) but unlike PRE-084, DTG
is an agonist of both Sigma-1 and Sigma-2. We wanted to see the effects of DTG on
barrier function of HUVEC cells. HUVEC cells were treated with DTG 10 µM or 30 µM.
30 µM of DTG caused a significant increase in TER after 1.5 hours (Figure 26).
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Discussion and Conclusions
Our results show that σ1 knockdown cells had less barrier function. They
expressed significantly less amounts of PECAM-1. The contribution of the junctional
protein PECAM-1 to endothelial barrier has been previously studied in detail (Privratsky
& Newman, 2014). Privratisky et al have shown that endothelial cells deficient in
PECAM-1 showed lower barrier function than control cells and that PECAM-1
homophilic interaction is the main cause for this mechanism (Privratsky et al., 2011). It
is important to note that the degree of TER drop noticed in PECAM-1 kd cells in three
different types of endothelial cells was comparable to that of σ1 kd cells in our study
(Figure 16). Due to the nature of σ1 receptors as chaperone proteins(Penke et al.,
2018), we suggest that they may affect translation and folding of the junctional protein
PECAM-1 and thus maintain a normal baseline barrier function.
Since PECAM-1 also plays an important role in shear stress sensing (Fleming et
al., 2005; Tzima et al., 2005), it is suggested that its deficiency in σ1 kd cells may impair
them from proper shear stress sensing which needs to be studied in detail. Another
study also showed that PECAM-1 is involved in the shear stress induced activation of
eNOS by a mechanism involving STAT3 phosphorylation and nostrin gene
expression(McCormick et al., 2011). This effect may explain the reason why σ1 kd cells
didn’t upregulate eNOS in response to shear stress (Fig 13).
Another key finding in the study is that σ1 agonist PRE-084 could partially
counteract IL-1β induced barrier disruption (Fig 25). IL-1β is an inflammatory mediator
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that is known to disrupt endothelial barrier. Argaw et al have shown that IL-1β regulates
blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program in
multiple sclerosis(Argaw et al., 2006). Others reported that Interleukin-1β increases
permeability in human renal glomerular endothelial cells(Du et al., 2015).
Moreover, it was shown that IL-1β induces inflammation by a mechanism
involving NF-KB and STAT1 (Pugazhenthi et al., 2013). Whether σ1 agonism by PRE084 counteracts other effects of IL-1β on endothelial cells remains to be studied in
detail. IL-1β has also been linked to mitochondrial damage in cases of diabetic
retinopathy (Kowluru et al., 2011). Our lab has recently published a finding that
mitochondrial damage caused by antimycin A caused disruption of barrier function of rat
intestinal microvascular endothelial cells(Alves et al., 2019). The specific contribution of
σ1 to endothelial bioenergetics will be studied in detain in chapter five. The barrier
enhancement caused by σ1 was tested using two agonists PRE-084 and DTG; also
was applied in four cell types; HUVEC, HDMEC, HLEC, RBMEC showing the
consistency of mechanism of action of σ1 in barrier enhancement.
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Figures

Figure 16. σ1 contributes to baseline endothelial barrier function.
A, Traces of the time course of the changes in mean TER starting immediately after
HUVEC were transfected with either non-targeting RNA (NT) or SIGMAR1 siRNA (σ1
kd) and seeded onto ECIS electrodes. N = 14 wells per group. Comparison was done
using repeated-measures ANOVA followed by Sidak’s multiple comparison test. B, The
difference in mean TER between the two groups at the 70 h post transfection time point
showing all data points is expanded here. C and D. Western blot confirming knockdown
of σ1 in the cells transfected with SIGMAR1 siRNA compared to non-targeting RNA
control at 48 h and 70 h. β-actin, which served as a loading control, is also shown. E.
Mean band intensities of σ1 normalized to β actin for the σ1 kd and NT groups at 48 h
and 70 h (n=4/group); analysis done by two-way ANOVA followed by Sidak’s multiple
comparison test. P values are shown for differences considered significant (p < 0.05).
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A, 48 h

B, 72 h

Figure 17. σ1 kd cells have less PECAM-1.
A, Western blotting of protein lysates from sigmar1 siRNA transfected cells and non
targeting RNA transfected cells. B, scatter blots represents fold changes of the protein
levels among the 2 groups. *p<0.05. Analysis was done using t-test.
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Figure 18. The σ1 agonist PRE-084 elevates endothelial barrier function.
A, Traces showing the time course of changes in normalized TER of confluent HUVEC
monolayers treated with the shown concentrations of PRE-084. The TER values were
normalized to the time point just prior to treatment with PRE-084 or vehicle control (time = 0
h). B, The individual and mean normalized TER values for each group after 3 hours of
PRE-084 or vehicle control treatment are shown. One-Way ANOVA followed by Dunnett’s
multiple comparison test was used for analysis. N=4 HUVEC monolayers per group. P
values are shown for differences considered significant (p < 0.05).
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Figure 19. PRE-084 elevates barrier function of human dermal microvascular
endothelial cell (HDMEC) monolayers
A, Traces showing the time course of changes in TER of HDMEC treated with the shown
concentrations of PRE-084. B, The bar graph represents the differences in TER after 8
hour of PRE-084 treatment. *p<0.05 compared to control. Analysis was done by One-Way
ANOVA followed by Dunnett’s multiple comparison test. N=4/group.
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Figure 20. PRE-084 elevates barrier function of human lung microvascular
endothelial cell (HLEC) monolayers.
A, Traces showing the time course of changes in TER of HLMEC treated with the shown
concentrations of PRE-084. B, The bar graph represents the differences in TER after 16
hour of PRE-084 treatment. *p<0.05 compared to control. Analysis was done by One-Way
ANOVA followed by Dunnett’s multiple comparison test. N=3 or 4/group.
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Figure 21. PRE-084 enhances TER in RBMEC.
cells were treated with the shown concentrations of PRE-084 at time=0. Bar graph
represents differences at 3 hours. Analysis was done using One-Way ANOVA, n=4/group.
*p<0.05, **p<0.005, ***p<0.0005.
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Figure 22. Effect of BD1047 on endothelial barrier integrity of HUVECs.
BD 1047 added at 300 nM concentration caused a significant drop of TER at 14 h.
n=4/group. Two-way ANOVA was used for analysis.

68

Figure 23. PRE-084 fails to enhance endothelial barrier function in the siRNAmediated knockdown of σ1.
A. The traces show changes in mean TER in the non-targeting RNA (NT) and
SIGMAR1 siRNA-mediated knockdown (σ1 kd) groups, before after treatment with 100
µM PRE-084 or vehicle at time t=0 h. B. Time-dependent changes in barrier function in
response to PRE-084 or vehicle for each group are also shown using normalized TER
values. Normalized TER was calculated by dividing values at each time point by the
TER value just prior to the addition of PRE-084 or vehicle (t = 0 h). C. Expanded
individual and mean TER for each group is shown for the time point at 3 h after addition
of vehicle or 100 µM PRE-084. Data were analyzed by two-way ANOVA followed by
Sidak’s test. D. Expanded data for the change in TER (%) from t = 0 h for each group at
3 h after the addition of vehicle or PRE-084 is also shown. T test and two-way ANOVA
with Sidak’s multiple comparison test were used for analysis. N= 6-8 HUVEC
monolayers per group. P values are shown for differences considered significant (p <
0.05). Some time points in panel B appear no to have an error bar because data had
less SEM than the size of the symbol.
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Figure 24. PRE-084 partially rescues TER drop in IL-1β treated HUVEC cells.
A, Traces of changes in TER with time in IL-1β 15 ng/ml treated cells in presence or
absence of PRE-084 100 µM. PRE-084 was added at time=0 followed by IL-1β 5 min after.
B, scatter blot represents TER differences at 3 h. Sigma-1R kd cells have less TER in
response to inflammatory challenge. C, Traces of the changes in TER of HUVEC cells
transfected with sigmar1 siRNA or non targeting RNA (con) in response to IL-1β 15 ng/ml)
or vehicle added at time 0. D, Scatter blot represents difference in TER at 2 h between
Non-targeting transfected cells and sigmar1 kd cells exposed to IL-1β.
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Figure 25. DTG elevates barrier function of human umbilical vein endothelial cell
(HUVEC) monolayers.
A, Traces showing the time course of changes in TER of HUVEC treated with the shown
concentrations of DTG. B, The bar graph represents the differences in TER after 1.5 hour
of DTG treatment. *p<0.05. Analysis was done by One-Way ANOVA followed by Dunnett’s
multiple comparison test. N=3/group.
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Chapter Five:
Sigma-1 activation and endothelial metabolic pathways
5a. Introduction:
Endothelial cells rely more on glycolysis for energy production than oxidative
phosphorylation despite the fact that they are exposed to blood with high levels of
oxygen (Eelen et al., 2015). Glycolysis has been proven preferable for ATP production
in endothelial cells as it allows for fast ATP production during vessel sprouting or
changing cytoskeletal dynamics that could be accomplished under hypoxic conditions
independent of oxygen. Not only glycolysis in ECs allows for ATP production, but also
for generation of macromolecules needed during cell division such as nucleotides via
pentose phosphate pathway(Bierhansl et al., 2017). Despite the significant contribution
of glycolysis to endothelial function, there is lack of studies determining its effects on
endothelial barrier integrity.
In addition to the well-known contribution of endothelial junctional proteins and
cytoskeleton dynamics in endothelial health(Gavard & Gutkind, 2006; Shen et al., 2009;
Lengfeld et al., 2017), bioenergetics have emerged as novel regulators of endothelial
function(Tang et al., 2014; Elmorsy & Smith, 2015; Rellick et al., 2016). Our lab has
recently published a finding that agents that inhibit mitochondrial complex 3 as
antimycin-A can negatively regulate endothelial barrier function(Alves et al., 2018).
Another finding in the same study links microvascular hyper permeability after
hemorrhagic shock and resuscitation to and mitochondrial oxidative phosphorylation.
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Despite the significant contribution of glycolysis to endothelial function, there is
lack of studies determining its effects on endothelial barrier integrity. σ1 is known to
maintain mitochondrial integrity, improve cell survival and stress response via
mitochondria and regulate oxidative stress derived from mitochondria based on their
localization at mitochondria associated ER membrane (De Bock et al.) in neurological
models(Goguadze et al., 2019). However, there is lack of studies about σ1 effects in
regard to endothelial mitochondria or bioenergetics particularly glycolysis. The present
study will outline its role in maintaining endothelial barrier integrity with respect to
endothelial bio-energetics.

5b. Results:
5b.i. Impact of Sigma-1 on CCCP induced barrier disruption
We wanted to test whether the barrier enhancing properties of PRE-084 extends
to counteracting barrier disruption caused by cellular energy depletion. Because of the
previous involvement of σ1 in bioenergetics in an other model(Abdullah et al., 2018),
and the lack of studies showing its effects on endothelial energy production, we chose a
model that mimics ischemic conditions and energy failure using the mitochondrial
uncoupler, Carbonyl cyanide m-chlorophenyl hydrazone (CCCP). CCCP is a
protonophore that is known to derive inward proton gradient across mitochondrial
membrane causing disruption of mitochondrial depolarization and uncoupling oxygen
consumption from ATP production(Lim et al., 2001; Ganote & Armstrong, 2003; Zhang
et al., 2016b). Despite its effects on disrupting mitochondrial function and oxidative
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phosphorylation in various models(Narendra et al., 2008), its effects on endothelium or
endothelial barrier weren’t previously documented. In our experiments, CCCP caused a
time dependent slow and sustained drop in TER as expected. Prior treatment with PRE084 could significantly attenuate this effect (figure 27). These findings suggest that σ1
activation could be beneficial in counteracting mitochondrial stress injuries.

5b.ii. PRE-084 effect on mitochondrial bioenergetics.
Given that activation of σ1 rescues the barrier disruption caused by CCCP, we
next were interested to study the previously unknown contributions of σ1 in endothelial
bioenergetics. We started experimenting by doing cell mito-stress test using seahorse
analyzer system. We saw a significant reduction of oxygen consumption rate, basal
respiration and mitochondrial ATP production in cells treated with PRE-084 (Figure 28).

5b.iii. PRE-084 effect on glycolysis and ATP production.
We focused in studying glycolysis as it was proven to be the main energy
production pathway in endothelial cells (Eelen et al., 2015). We used glycolytic rate
assay with Seahorse Agilent technology system (glycolytic rate assay and ATP rate
assay) to validate the effects of σ1. This system allows for measurement of total proton
efflux rate (PER) and glycolytic proton efflux rate (glycoPER) and uses these 2
parameters to calculate for glycolytic rates as shown in Agilent seahorse glycolytic rate
assay profile (Figure 29,A). The ATP rate assay utilizes extracellular acidification rate
(ECAR) and oxygen consumption rate (OCR) to calculate differential ATP levels from
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either mitochondrial respiration or anaerobic glycolysis (Figure 30 A) ). Our results show
that the HUVEC cells treated with PRE-084 100 µM for three hours prior to the assay
showed higher glycoPER (Figure 31 B), Lower OCR (Figure 31 C). Then we compared
the individual assay parameters between the 2 groups using data from seahorse report
generator. We found that treatment with σ1 agonist PRE-084 caused significant
elevation of basal glycolysis, compensatory glycolysis, %PER from glycolysis, basal
proton efflux rate (figure 29 D-F). PRE-084 significantly elevated glycolytic ATP
production levels (Figure 30 D). Notably, PRE-084 decreased mitochondrial ATP
production and mitochondrial OCR/ Glyco PER ratio (Figure 30 E, Figure 29G) without
changing the total amount of ATP (Fig 30 F). The results suggest that σ1 activation may
be linked to enhancing glycolytic pathway and shifting towards greater glycolytic ATP
production rather that changing the total amount of ATP.

5b.iv. Bioenergetics of sigma-1 kd cells.
Glycolytic rate assay was conducted on σ1 kd cells vs NT cells. Results show
that σ1 kd cells didn’t have difference in ECAR and had less OCR than control cells.
They also had less mito OCR/ glycoPER (Figure 31).

5. v. Response of σ1 kd cells to PRE-084
Next we wanted to evaluate the response of σ1 kd cells to PRE-084 regarding
energy production. We conducted glycolytic rate assay and saw that PRE-084 didn’t
increase glycoPER in σ1 kd cells and apparently decreased OCR (figure 32 A,B).
Comparing individual assay parameters, σ1 kd cells treated with PRE-084 didn’t have
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different levels of basal glycolysis, proton efflux rate, mito OCR/ glycoPER (Figure 32
C,E,F). Interestingly, σ1 kd cells treated with PRE-084 had less compensatory
glycolysis (Figure 32 D) and less post 2-DG acidification than non treated ones (Figure
32 G). The results confirm the role of σ1 in PRE-084 induced enhancement of glycolysis
but doesn’t explain the counter-effect of PRE-084 in σ1 kd cells.

5. vi. The effect of afobazole on glycolytic rate
In order to have a more comprehensive overview on σ1 effect on glycolysis, we
used another sigma-1 agonist, Afobazole to conduct the same glycolytic rate assay
shown before. Cells were treated with afobazole 300 µM for three hours before the
assay. Cells had higher glycoPER (Figure 33 A), lower oxygen consumption rate
(Figure 33 B), higher proton efflux rate (Figure 33 D) and lower mitoOCR/ glycoPER
(Figure 33 F) indicating that afobazole may have a role in endothelial bioenergetics
similar to PRE-084.

Discussion and Conclusions
One of the key findings in this study is that σ1 activation could not only elevate
barrier function in stable cells, but also could counteract cellular stress induced TER
drop in cases of challenging the cells with CCCP suggesting σ1’s role in endothelial
barrier modulation (Figure 27). CCCP is known to cause mitochondrial damage and
energy depletion (Nieminen et al., 1994; Narendra et al., 2008; Kowluru et al., 2011).
Our finding that σ1 activation enhances glycolysis and glycolytic ATP production,
suggests that the mechanism by which σ1 activation counteracts such insults may be
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compensatory upregulation of glycolysis to maintain a considerable amount of ATP
sufficient for baseline barrier function maintenance (Figure 30). This assumption is
consistent with a previously reported finding that agents that enhance glycolysis such as
fructose could counteract CCCP induced cell toxicity by glycolytic ATP formation rather
than by preserving mitochondrial membrane potential (Nieminen et al., 1994). Annalisa
Zecchin et al have highlighted multiple advantages of using glycolysis by ECs as the
primary source of energy as this how, ECs can spare oxygen for usage by perivascular
cells. Moreover, a reduction in mitochondrial respiration decreases reactive oxygen
species (ROS) generated and thus promoting healthy endothelium(Zecchin et al.,
2017). It was also shown that glycolysis regulatory enzymes such as PFK associate
with actin cytoskeleton and lamellopodia causing cytoskeletal protrusions during vessel
sprouting (De Bock et al., 2013). Lamellopodia are known to be tightly involved with
endothelial barrier function (Breslin et al., 2015a). Glycolytic ATP production has also
been shown through experimental and computational modeling to modulate cellular
rearrangement(Cruys et al., 2016). Moreover, active spatiotemporal patterns of ATPdependent signaling at the cell periphery is evident when endothelial cell monolayers
are stimulated to enhance their barrier function (Zhang et al., 2016a)
An interesting finding that PRE-084 decreased the ability of σ1 kd cells to
compensatory up-regulate glycolysis to meet cellular energy demands (Figure 32)
suggests its complex role in cellular energetics that needs to be studied in detail.
In conclusion, to our knowledge, this is the first study to show the significant
contribution of σ1 receptors in maintenance of endothelial barrier function in basal levels
and after challenge of barrier disrupters. Our data show for the first time that σ1
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activation leads to enhancing glycolysis and subsequent glycolytic ATP production
which is tightly linked to enhancing endothelial barrier whereas σ1 deficiency led to
disruption of barrier function. The shown evidence that σ1 can shift energy production
from mitochondrial to glycolytic suggests that the barrier protective properties can be
beneficial in ischemic conditions and independent of oxygen. The work suggest that σ1
as a novel therapeutic target for ameliorating endothelial barrier dysfunction caused by
ischemia, providing new mechanistic insight about the σ1 agonists under investigation
as therapeutics (Zamanillo et al., 2013; Mavlyutov et al., 2017; Smith et al., 2018).

78

Figures

Figure 26. PRE-084 partially reduces endothelial barrier dysfunction caused by
the mitochondrial oxidative phosphorylation uncoupler CCCP.
A. Traces of mean normalized TER over time in cells treated with 10 µM of CCCP in the
presence or absence of 100 µM PRE-084 pretreatment for 5 minutes are shown; PRE084 was added at time t=0 h and CCCP five minutes later. B. Mean normalized TER at
4 hours post treatment for each group. N=8 HUVEC monolayers for each group.
Analysis was done by two-way ANOVA followed by Sidak’s multiple comparison test. P
values are shown for differences considered significant (p < 0.05).
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Figure 27. PRE-084 decreases oxygen consumption and ATP production in
HUVECs.
Cells were treated with PRE-084 100 µM for 3 hours then subjected to the Agilent
seahorse cell mito-stress test protocol. N=3/group. P<0.05.
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Figure 28. PRE-084 enhances glycolysis in HUVEC.
Confluent HUVEC monolayers were treated either with 100 µM PRE-084 or vehicle
control for 3 h and then subjected to the glycolytic rate using the Agilent Seahorse XFp
system. A. Assay profile of the glycolytic rate assay obtained from Agilent Technologies.
© Agilent Technologies, Inc, Reproduced with Permission, Courtesy of Agilent
Technologies, Inc.The glycolytic rate assay determines the glycolytic proton efflux rate
(glycoPER, panel B) and the oxygen consumption rate (OCR, panel C) before and after
addition of a rotenone/antimycin-A cocktail (Rot/AA) and then addition of 2deoxyglucose (2-DG). Additional parameters calculated from the glycolytic rate assay
include basal glycolysis (D), compensatory glycolysis (E), basal proton efflux rate
(PER)(F), the ratio of mitochondrial OCR to GlycoPER (G) and post 2-DG acidification
(H). The two groups were compared using an unpaired t-test for each parameter. N=9
HUVEC monolayers for each group. P values are shown for differences considered
significant (p<0.05).
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Figure 29. PRE-084 enhances glycolytic ATP production in HUVEC.
Confluent HUVEC monolayers were treated either with 100 µM PRE-084 or vehicle
control for 3 h and then subjected to the ATP production rate assays using the Agilent
SeaHorse XFp system. The ATP production rate assay determines the extracellular
acidification rate (ECAR) and oxygen consumption rate (OCR) before and after addition
of oligomycin and later the rotenone/antimycin-A cocktail. A. assay profile obtained from
Agilent Technologies. © Agilent Technologies, Inc, Reproduced with Permission,
Courtesy of Agilent Technologies, Inc.
B. OCR and C. ECAR of control cells and PRE-084 treated cells. Additional parameters
calculated from the ATP production rate assay include the glycolytic ATP (D),
mitochondrial ATP (E), and total ATP (F) production rates. The two groups were
compared using an unpaired t-test for each parameter. N=9 HUVEC monolayers for
each group. P values are shown for differences considered significant (p<0.05).
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Figure 30. Sigma-1 kd cell glycolytic assay profile.
Cells were treated with sigma-1 siRNA 200 nM for 72 hours before the assay. A.
Glycolytic proton efflux rate (GlycoPER), B. oxygen consumption rate. D-G assay
parameters obtained from seahorse report generator. N=12/group. T-test was used for
analysis
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Figure 31. PRE-084 fails to enhance endothelial glycolytic rate after siRNAmediated knockdown of σ1.
At 70 h post-transfection, confluent HUVEC monolayers transfected with SIGMAR1
siRNA (σ1 kd) were treated with PRE-084 or vehicle for 3 h. A. Time course of glycolytic
proton efflux rate (GlycoPER) of σ1 kd cells vs NT control cells during the glycolytic rate
assay, in which cells were treated with a rotenone/antimycin-A cocktail (Rot/AA) and
later with 2-deoxyglucose (2-DG). B, Oxygen consumption rate (OCR) during the same
assay. Additional parameters were calculated from the assay for basal glycolysis (C),
compensatory glycoclysis (D), basal protein efflux rate (E), the ratio of mitochondrial
oxygen rate (mito OCR) to GlycoPER, and the post-2-deoxyglucose acification (G). The
two groups were compared with unpaired t-tests for each parameter. P values for
differences considered significant (p < 0.05) are shown. N=6 HUVEC monolayers per
group.
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Figure 32. Afobazole enhances glycolytic proton efflux rate
(A) and lowers oxygen consumption rate in HUVEC (B). C, D, E, F; assay parameters
obtained form glycolytic rate assay. Afobazole 300 µM or vehicle was used to treat cells 3
hours prior to the assay.
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Chapter Six:
Sigma-1 receptor effects in lymphatic endothelium
6 a. Introduction:
The lymphatic system has an important role in fluid homeostasis, lymph
transport, lipid trafficking and immunity (Breslin, 2014). Lymphatic dysfunction leads to a
disease called lymphedema (Kayiran et al., 2017). Lymphatic collection starts with the
lymphatic capillaries and initial lymphatic vessels which are composed of a single layer
of lymphatic endothelial cells without smooth muscle cell coverage which increases as
vessels carry lymph back to blood circulation (Kesler et al., 2013; Breslin et al., 2018).
Lymphatic capillaries are composed of a single, non-fenestrated endothelial cell
layer, that is well suited for the uptake of fluid, macromolecules, and cells. LECs share
some common properties with the endothelium of blood vessels, but they also differ at
the ultrustructural level. Lymphatic capillaries are featured by irregular and wider lumen
than blood capillaries, and their endothelium is lessened. Another major difference is
that lymphatic capillaries have an incomplete basement membrane and are not
supported by pericytes(Pepper & Skobe, 2003). Lymphatic endothelial cells have been
isolated and characterized showing their main markers including CD31, CD34,
podoplanin, VEGFR-3 and nuclear marker PROX-1, LYVE-1 (Podgrabinska et al., 2002;
Lokmic, 2016).
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Lymphatic endothelial cells compose a barrier between the lymph and interstitial
compartments which is important for lymphatic and tissue homeostasis (Cromer et al.,
2014). The integrity of endothelial barrier in response to cytokines has been previously
studied(Cromer et al., 2014). The barrier function of lymphatic endothelium decreased
in response to cytokines such as TNF-α, IL-6, IL-1β, IFN-γ and LPS that was consistent
with reduction the expression of VE-cadherin and increase in scavenging of β-catenin
and changes in cytoskeleton(Cromer et al., 2014). This suggests that the lymphatic
barrier is affected by inflammation and that some inflammatory signals may cause
increases in permeability.
Endothelial Bioenergetics is an important factor affecting lymphatic endothelium.
The lymphatic endothelium exists in a distinctive metabolic environment. The lymphatic
fluid is rich in nutrients, even though it is the product of excess fluid from tissues(Lee et
al., 2018). LECs are exposed to high concentrations of glucose (4–6 mM), protein (8–32
g/L), and triglycerides (8–40 mg/dL)(McCaul et al., 2000). Whereas oxygen
concentration in the lymphatic fluid in the thoracic duct and capillary lymphatics is
relatively low with partial pressure of oxygen (pO 2) 15–42 mmHg in the lymph
compared with 80–100 mmHg in the arterial blood(Witte et al., 1967). This environment
may account for the metabolic specifications of the lymphatic endothelium.
It has been well documented that endothelial cells rely more on glycolysis for
energy production with 99% of glucose converts anaerobically to lactate and only 0.04%
undergoes oxidative phosphorylation(Krutzfeldt et al., 1990). Similar to blood
endothelium, LECs have also been reported to take up massive amounts of glucose
compared with other cell types and to use glycolysis as the primary source of ATP
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(~85%) with mitochondrial glucose oxidation almost completely inactive(De Bock et al.,
2013). The cells mostly prefer glycolysis possibly as glycolysis allows for ATP
generation at cell locomotion sites such as lamellopodia and filopodia and also
glycolysis maximizes ATP use under their low oxygen environment and spares the need
to transfer ATP from mitochondria(Barankay et al., 1976; Teuwen et al., 2019).
Sigma-1 receptors have been evidenced and reported functional in lymphatic
vessels. Agonism of σ1 by afobazole has been shown to cause dilation of isolated rat
lymphatic vessels(Trujillo et al., 2017). However, exact role of σ1 receptors in other
aspects of lymphatic endothelial health hasn’t been previously well identified. Due to the
shown results of effects of σ1 agonism on barrier function and energetics of HUVECs
and other blood endothelial cell, we hypothesized that σ1 will have a role in maintaining
of lymphatic endothelial barrier function and stabilizing energy production.
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6 b. Results:
6 b. i. PRE-084 enhances TER of HDLEC:
To assess the impact of σ1 activation on lymphatic endothelial barrier function,
confluent HDLEC monolayers were treated with the selective σ1 agonist PRE-084 at
concentrations ranging from 1 – 200 µM (Fig. 34 A). PRE-084 caused enhancement of
TER concentration dependently that started around 4 hours post treatment and was
sustained till the end of the experiment at 18 hours (Figure 34 A). Concentrations
starting at 50 µM elicited a significant increase in HDLEC monolayer TER at 8 hours
(Figure 34 B) and concentrations starting at 100 µM showed a significant TER
enhancement at 18 hours (Figure 34 C). 100 µM concentration was chosen for the
subsequent experiments.
6 b. ii. BD1047 decreases TER of HDLEC:
We next wanted to test whether the σ1 antagonist BD1047 has an effect on
HDLEC barrier function. HDLEC were treated with BD1047 with concentrations ranging
from 100 nM to 50 µM. The highest concentration of 50 µM of BD1047 caused a
significant drop of TER at 20 hours (Figure 35). However, we couldn’t conclude that
sigma-1 antagonism on its own causes a disruption in barrier function as 50 µM is
considered a very high concentration for BD1047 that may also allow for off target
effects and non specific bindings.
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6 b. iii. Sigma-1 kd cells had less TER:
We next wanted to further validate the contribution of σ1 to baseline barrier
function of HDLEC using a genetic approach by selective siRNA mediated knockdown
of sigma-1 receptor. Consistent with our previous findings with HUVECs, we saw a
decrease in TER in σ1 knockdown cells starting at around 48 hours post transfection
and continuing to drop till the end of the experiment. The drop in TER was significant
and σ1 knockdown cells decreased their resistance to almost 50% less than the nontargeting transfected cells. The decrease in resistence was consistent with the
diminished sigma-1 protein level expression by western blotting at 70 h post transfection
(Figure 36)

6 b. iv. PRE-084 attenuated IL-1β induced TER drop in HDLEC:
We next wanted to validate whether the barrier enhancing properties of the σ1
agonist PRE-084 also involves barrier restoration in inflammatory conditions. Cells were
treated with IL-1β 15 ng/ml in the presence or absence of PRE-084 100 µM. iL-1β
caused a significant drop in TER in HDLEC monolayer that reversed by the presence of
PRE-084. Of note, PRE-084 only caused enhancement of TER as expected (Figure 37).
The results suggest a possible anti-inflammatory role of σ1 agonism in lymphatic
endothelium

6 b. v. PRE-084 enhances glycolysis in HDLEC:
We were interested to examine whether PRE-084 causes enhancement of
glycolysis in HDLEC similar to our results in HUVECs. We conducted a glycolytic rate
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assay on cells pre-treated with PRE-084 for 24 hours. We saw a significant
enhancement of basal glycolysis and compensatory glycolysis as well as basal proton
efflux rate in cells treated with PRE-084 (Figure 38). Treated cells also had lower
mitoOCR/ glycoPER ratio indicating that σ1 agonism shifts the lymphatic endothelial cell
energy production towards enhancement of glycolysis (Figure 38).

Discussion and Conclusions
Lymphatic system has a crucial importance in body homeostasis(Olszewski,
2003). There are many disease conditions involving lymphatic dysfunction including but
not limited to Lymphedema, inflammation and lymphangitis (Cueni & Detmar, 2008;
Cohen et al., 2016). Lymphedema is a progressive disease characterized by improper
function of lymphatic vessels in lymph collection and fluid regulation. It can be either
primary congenital lymphedema or secondary to a surgical procedure such as breast
cancer removal (Greene & Goss, 2018). Patients with lymphedema suffer from limb
swelling, tightness, sensation of fullness, redness and limitation of movement(Paskett,
2015). It has been critically difficult to completely cure lymphedema. The effective ways
to reduce morbidities has been conservative therapies such as compression, physical
therapy, pain relievers, anti-inflammatories or surgical removal(Ly et al., 2017).
Efforts are constantly made to understand the mechanisms underlying lymphatic
dysfunction with hope to develop new therapeutics. Lymphatic valve impairment is a key
factor influencing pathobiology of lymphedema. Yang et al have shown that VECadherin signaling is essential for lymphatic valve formation and maintenance (Yang et
al., 2019b). Notably, Lymphatic endothelial cells (LECs) actively participate in the
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phenotypic consequences of a deranged lymphangiogenesis relating to tissue fluid
accumulation in the pathogenesis of lymphedema(Ji, 2008).
Lymphatic barrier dysfunction is also a common pathology that contributes to
lymphatic diseases(Scallan et al., 2016). There is a need to develop new strategies to
strengthen lymphatic endothelium to counteract such pathologies. Our findings showed
that σ1 agonism could enhance barrier function of LECs (Figure 34). The specific
contribution of σ1 to lymphatic endothelial barrier was shown using a model of σ1 kd
LECs which showed deficient barrier function compared to controls. Lymphatic
dysfunction is also related to inflammation and accumulation of inflammatory mediators
such as IFN-γ, IL-1, IL-13, IL-4, IL-6, TGF-β1, VEGF-C(Ly et al., 2017). Our finding that
PRE-084 could counteract IL-1β induced barrier disruption in LECs suggest a possible
anti inflammatory role that can be beneficial in cases such as lymphedema.
Lymphedema is also characterized by oxidative stress and metabolic impairments such
as accumulation of reactive oxygen species(Siems et al., 2002).
Our results suggested the ability of PRE-084 to enhance glycolysis over
mitochondrial oxygen consumption as a method to spare oxygen, limit ROS formation
and also contribute to barrier enhancement. Collectively, our results suggest σ1 as an
important modulator of lymphatic endothelial function that can be applied as a
therapeutic target.
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Figures

Figure 33. The σ1 agonist PRE-084 elevates endothelial barrier function in HDLEC
HDLEC cells were treated with PRE-084 or Vehicle at time t=0. A. Time courses of
changes in TER with PRE-084 of vehicle control. B. Scatter plots showing differences at
8 h after addition of PRE-084. C. Scatter plots showing differences at 18 h after addition
of PRE-084 N=4 for each group. Groups were compared with 1-way ANOVA and
Dunnett’s multiple comparison test.
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Figure 34. Effect of BD1047 on TER of HDLEC.
HDLEC cells were treated with the σ1 antagonist BD1047 with the shown
concentrations. Treatment was added at time t=0. A, Traces showing TER differences
over time. B, Scatter plots represent changes in TER at 2 hours. n=8/group.
One-Way ANOVA with Dunnett’s multiple comparison test was used for analysis.
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Figure 35. Sigma-1 receptor is important for maintenance of lymphatic baseline
barrier integrity
A,Traces showing TER differences in σ1 knockdown cells compared to non-targeting
control. B, Scatter plots represents TER differences at 70 h post transfection
n=16/group. Western blot analysis of σ1 expression and b-actin in σ1 kd and non
targeting control cells.
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Figure 36. PRE-084 partially attenuates IL-1β induced TER drop.
A. Time course of TER changes in HDLEC treated with 100 µM PRE-084 or vehicle
control for 5 minutes followed by addition of 15 ng/ml IL-1β or vehicle. B. Mean TER for
each group at 8 hours post treatment. N=12/group. Analysis was done by two-way
ANOVA followed by Sidak’s multiple comparison test.
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Figure 37. PRE-084 enhances glycolysis in HDLEC monolayer.
A, Glycolytic Rate Assay of PRE-084 treated HDLEC. Cells were treated with PRE-084
18 hours before the assay. Traces showing changes in proton efflux rate. B, Scatter
blots showing different assay parameters obtained from Agilent seahorse report
generators. N=3/group. T-test was used for analysis.
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Chapter Seven: Overall Conclusions and future
directions
7.a Conclusions:
Sigma-1 receptors have gained considerable attention pertaining to neuroprotection and cardio-protection. We introduce a novel aspect of σ1 functional
significance regarding endothelial health. The importance of endothelial dysfunction in
many disease pathologies has raised attention regarding finding therapeutics that act by
enhancing endothelial function. Our results showed that σ1 has the potential to
modulate endothelial NO production and eNOS activity. We also showed some effects
of σ1 agonism on endothelial barrier maintenance and counteracting inflammation
induced barrier disruption. σ1 could also affect endothelial bioenergetics and enhance
glycolysis in endothelial cells. Collectively, our results suggest the endothelial protective
roles of σ1 regarding eNOS activation, barrier maintenance and energy preservation.
These three aspects highlight the previously unknown involvement of σ1 in endothelial
health with potential to address therapeutic interventions.

7.b Future Directions:
After showing the proposed mechanisms of σ1 induced eNOS activation and NO
production, the study is lacking validation of the mechanisms in an in vivo setting. A
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future study will include the significance of σ1 mediated endothelial protection in stroke
rat model of middle cerebral artery occlusion. Because stroke is known to cause blood
brain barrier damage, we are aiming to see whether sigma-1 activation can protect
blood brain barrier damage following stroke by Evans blue leakage assays. Another
potential avenue is investigation of other potential mechanisms of σ1 induced
vasodilation beyond endothelium, such as modulation of calcium trafficking in the
smooth muscle layers of blood vessels. More intracellular mechanisms can also be
examined by running transwell permeability assays in endothelial cells to get a precise
understanding on the effects of σ1 on endothelial permeability. We are also planning to
investigate more junctional proteins that could be involved in σ1 induced barrier
enhancement. Accurate understanding of the mechanisms by which σ1 agonism
enhances glycolysis is also required. Future studies may include tracking glycolysis
regulatory enzymes and their association with barrier enhancement or lamellopodia
protrusion. σ1 knock out mice are also being bred for future mechanistic studies about
important signaling pathways.
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